

Stock Code: 4123

Center Laboratories, Inc. and Subsidiaries
Consolidated Financial Statements and Independent Auditors' Review Report
For the Nine Months Ended September 30, 2025 and 2024

Address: 7F., No. 3-2, Park St., Nangang Dist., Taipei City, Taiwan (R.O.C.)

Tel: (02)2655-8680

Independent Auditors' Review Report

The Board of Directors and Shareholders of Center Laboratories, Inc.

Introduction

We have reviewed the accompanying consolidated balance sheets of Center Laboratories, Inc. and its subsidiaries as of September 30, 2025 and 2024, the related consolidated statements of comprehensive income for the three months ended September 30, 2025 and 2024, and for the nine months ended September, 2025 and 2024, the consolidated statements of changes in equity and cash flows for the nine months then ended, and the related notes to the consolidated financial statements (including a summary of significant accounting policies). Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34 “Interim Financial Reporting” endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

Scope of Review

Except as explained in the following paragraph, we conducted our reviews in accordance with the Standards on Review Engagements of the Republic of China 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”. A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Basis for Qualified Conclusion

The financial statements of non-significant subsidiaries were not reviewed by independent auditors. Those statements reflect total assets of NT\$4,798,184 thousand and NT\$6,890,684 thousand, constituting 18.6% and 26.5% of the consolidated total assets, and total liabilities of NT\$6,378 thousand and NT\$662,436 thousand, constituting 0.1% and 9.8% of the consolidated total liabilities as of September 30, 2025 and 2024, respectively; and total comprehensive (loss) income of NT\$(94,461) thousand and NT\$680,715 thousand, constituting (3.8)% and (235.0)% of the consolidated total comprehensive (loss) income for the nine months ended September 30, 2025 and 2024, respectively.

The valuation of investments accounted for using the equity method, which includes investments in associates, is based on the financial statements of those companies for the same period that were not reviewed by independent auditors. The investments accounted for using the equity method amounted to NT\$3,832,889 thousand and NT\$4,126,287 thousand, constituting 14.9% and 15.9% of the consolidated total assets as of September 30, 2025 and 2024, respectively. The share of profit (loss) from associates accounted for using the equity method amounted to NT\$59,720 thousand, NT\$77,509 thousand, NT\$51,029 thousand, and NT\$103,402 thousand for the three months ended September 30, 2025 and 2024, and for the nine months ended September 30, 2025 and 2024, respectively.

Qualified Conclusion

Based on our reviews and the review reports of other independent auditors, except for the adjustments to the consolidated financial statements, if any, as might have been determined to be necessary had the financial statements of non-significant consolidated subsidiaries and certain investments accounted for using the equity method been reviewed by independent auditors, that we might have become aware of had it not been for the situation described above, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of Center Laboratories, Inc. and its subsidiaries as of September 30, 2025 and 2024, and of its consolidated financial performance for the three months ended September 30, 2025 and 2024, and for the nine months ended September 30, 2025 and 2024 and its consolidated cash flows for the nine months ended September 30, 2025 and 2024, in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting,” that came into effect as endorsed by the Financial Supervisory Commission.

Other Matter - Making reference to the reviews of other independent auditors

For the aforesaid subsidiaries disclosed in the consolidated financial statements as of September 30, 2025, the consolidated financial statements of Bioflag International Corporation and its subsidiaries were not reviewed by the Group’s CPA. Those financial statements were reviewed by another auditor whose reports have been thereon furnished to us, and our opinions expressed herein, insofar as it relates to the amounts for the aforesaid subsidiaries, are based solely on the report of other auditor. Total assets of the consolidated financial statements amounted to NT\$1,932,084 thousand, constituting 7.5% of the consolidated total assets as of September 30, 2025; concurrently, total operating revenue amounted to NT\$119,682 thousand and NT\$401,763 thousand, constituting 33.33% and 35.98% of the consolidated total operating revenue for the three months ended September 30, 2025, and for the nine months ended September 30, 2025, respectively.

Among the invested companies accounted for using the equity method disclosed in the consolidated financial statements, the financial statements of BioGend Therapeutics Co., Ltd., Lumosa Therapeutics Co., Ltd., and Medeon Biodesign, Inc., were not reviewed by our CPA. Those financial statements were reviewed by another auditor whose reports have been thereon furnished to us, and our opinions expressed herein, insofar as it relates to the amounts included in the financial statements, are based solely on the report of other auditor. These investments accounted for using the equity method amounted to NT\$1,132,054 thousand and NT\$1,200,964 thousand, constituting 4.4% and 4.6% of the total assets as of September 30, 2025 and 2024, respectively. The share of profit (loss) from associates accounted for using the equity method amounted to NT\$(61,729) thousand, NT\$(141,694) thousand, NT\$(273,787) thousand and NT\$(297,095) thousand, constituting (1.9)%, (34.2)%, (9.0)% and 100.9% of the income before income tax for the three months ended September 30, 2025 and 2024, and for the nine months ended September 30, 2025 and 2024, respectively.

The engagement partners on the reviews resulting in this independent auditors' review report are Cheng, Chung-Hao and Chi, Chia-Yu.

Full-Fill & Co., CPAs

Taipei, Taiwan

Republic of China

November 11, 2025

Notice to Readers

The accompanying consolidated financial statements are intended only to present the consolidated financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally applied in the Republic of China.

For the convenience of readers, the independent auditors' review report and the accompanying consolidated financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' review report and consolidated financial statements shall prevail.

Center Laboratories, Inc. and Subsidiaries
Consolidated Balance Sheets
As of September 30, 2025, December 31, 2024, and September 30, 2024

Account Code	Assets	Notes	In Thousands of New Taiwan Dollars					
			September 30, 2025		December 31, 2024		September 30, 2024	
			Amount	%	Amount	%	Amount	%
11XX	Current assets							
1100	Cash and cash equivalents	6(1)	\$ 521,514	2	\$ 1,442,273	6	\$ 1,824,521	7
1110	Financial assets at fair value through profit or loss	6(2), 8	497,211	2	257,998	1	320,402	1
1136	Financial assets at amortized cost	6(3)	61,253	—	350,009	1	—	—
1150	Notes receivable, net		23,248	—	24,106	—	20,994	—
1170	Accounts receivable, net	6(4)	166,978	1	178,579	1	172,742	1
1200	Other receivables	7	9,484	—	11,367	—	9,896	—
130X	Inventories	6(5)	327,044	1	309,703	1	298,625	1
1476	Other financial assets	8	294,340	1	1,183,483	5	1,158,568	5
1470	Other current assets		21,595	—	23,989	—	26,722	—
11XX	Total current assets		<u>1,922,667</u>	<u>7</u>	<u>3,781,507</u>	<u>15</u>	<u>3,832,470</u>	<u>15</u>
15XX	Non-current assets							
1510	Financial assets at fair value through profit or loss	6(2), 8	15,643,769	61	13,048,724	51	13,510,902	52
1550	Investments accounted for using the equity method	6(6), 8	5,312,120	20	5,761,850	23	5,769,286	22
1600	Property, plant and equipment	6(7), 8	1,470,963	6	1,415,920	5	1,372,058	5
1755	Right-of-use assets	6(8)	10,838	—	17,080	—	19,380	—
1760	Investment property, net	6(9), 8	659,221	3	662,247	3	663,261	3
1780	Intangible assets	6(10)	745,062	3	780,347	3	792,106	3
1840	Deferred tax assets	6(22)	7,449	—	32,505	—	18,297	—
1920	Refundable deposits		9,295	—	9,127	—	8,444	—
1915	Prepayments		11,855	—	13,959	—	32,348	—
1975	Net defined benefit asset		16,181	—	13,909	—	9,078	—
15XX	Total non-current assets		<u>23,886,753</u>	<u>93</u>	<u>21,755,668</u>	<u>85</u>	<u>22,195,160</u>	<u>85</u>
1XXX	Total assets		<u><u>\$ 25,809,420</u></u>	<u><u>100</u></u>	<u><u>\$ 25,537,175</u></u>	<u><u>100</u></u>	<u><u>\$ 26,027,630</u></u>	<u><u>100</u></u>

(The accompanying notes are an integral part of the consolidated financial statements.)

Center Laboratories, Inc. and Subsidiaries

Consolidated Balance Sheets

As of September 30, 2025, December 31, 2024, and September 30, 2024

Account Code	Liabilities and Equity	Notes	In Thousands of New Taiwan Dollars					
			September 30, 2025		December 31, 2024		September 30, 2024	
			Amount	%	Amount	%	Amount	%
21XX	Current liabilities							
2100	Short-term loans	6(11), 8	\$ 980,000	4	\$ 1,262,000	5	\$ 1,292,000	5
2130	Contract liabilities	6(18)	154,147	1	159,246	1	177,022	1
2170	Accounts payable		107,765	—	134,790	—	113,908	—
2200	Other payables	6(12), 7	694,858	3	155,967	1	131,210	1
2230	Current tax liabilities	6(22)	62,964	—	277,325	1	239,249	1
2280	Lease liabilities	6(8)	9,230	—	9,214	—	9,228	—
2320	Long-term liabilities, current portion	6(11)(13)	1,750,360	7	2,595,827	10	1,983,217	7
2399	Other current liabilities	7	19,423	—	22,393	—	31,023	—
21XX	Total current liabilities		<u>3,778,747</u>	<u>15</u>	<u>4,616,762</u>	<u>18</u>	<u>3,976,857</u>	<u>15</u>
25XX	Non-current liabilities							
2500	Financial liabilities at fair value through profit or loss	6(2)	53,568	—	46,158	—	31,945	—
2527	Contract liabilities	6(18)	—	—	4,841	—	—	—
2530	Bonds payable	6(13)	594,982	2	2,234,917	9	2,211,003	9
2540	Long-term loans	6(11), 8	1,116,035	4	419,998	2	222,820	1
2570	Deferred tax liabilities	6(22)	626,021	3	148,741	—	284,488	1
2580	Lease liabilities	6(8)	1,737	—	8,173	—	10,469	—
2670	Other non-current liabilities	7	906	—	3,102	—	5,576	—
25XX	Total non-current liabilities		<u>2,393,249</u>	<u>9</u>	<u>2,865,930</u>	<u>11</u>	<u>2,766,301</u>	<u>11</u>
2XXX	Total liabilities		<u>6,171,996</u>	<u>24</u>	<u>7,482,692</u>	<u>29</u>	<u>6,743,158</u>	<u>26</u>
31XX	Equity attributable to shareholders of the parent	6(15)						
3110	Share capital		7,249,768	28	7,249,768	28	7,249,768	28
3150	Stock dividends to be distributed		362,488	1	—	—	—	—
3200	Capital surplus		5,041,077	20	5,535,957	22	5,950,046	23
3300	Retained earnings							
3310	Legal reserve		—	—	1,267,810	5	1,267,810	5
3320	Special reserve		5,002,321	19	5,560,363	22	5,560,363	21
3350	Unappropriated earnings		2,623,443	10	(1,368,634)	(5)	(608,482)	(2)
3400	Other equity							
3410	Exchange differences arising on translation of foreign operations		(68,551)	—	(739)	—	(208)	—
3420	Unrealized gain (loss) on financial assets at fair value through other comprehensive income		19,603	—	19,603	—	74,820	—
3500	Treasury shares		<u>(592,731)</u>	<u>(2)</u>	<u>(209,651)</u>	<u>(1)</u>	<u>(209,651)</u>	<u>(1)</u>
31XX	Total equity attributable to shareholders of the parent		<u>19,637,418</u>	<u>76</u>	<u>18,054,477</u>	<u>71</u>	<u>19,284,466</u>	<u>74</u>
36XX	Non-controlling interests	6(15)						
3XXX	Total equity		<u>19,637,424</u>	<u>76</u>	<u>18,054,483</u>	<u>71</u>	<u>19,284,472</u>	<u>74</u>
1XXX	Total liabilities and equity		<u>\$ 25,809,420</u>	<u>100</u>	<u>\$ 25,537,175</u>	<u>100</u>	<u>\$ 26,027,630</u>	<u>100</u>

(The accompanying notes are an integral part of the consolidated financial statements.)

Center Laboratories, Inc. and Subsidiaries
Consolidated Statements of Comprehensive Income
For the three months and nine months ended September 30, 2025 and 2024

Account Code	Items	Notes	In Thousands of New Taiwan Dollars, Except Earnings Per Share							
			Three Months Ended September 30				Nine Months Ended September 30			
			2025	2024	2025	2024	2025	2024	2025	2024
4000	Net revenue	6(18)	\$ 359,107	100	\$ 392,486	100	\$ 1,116,677	100	\$ 1,169,315	100
5000	Cost of revenue		215,415	60	210,381	53	662,996	59	631,518	54
5900	Gross profit		143,692	40	182,105	47	453,681	41	537,797	46
6000	Operating expenses	6(19), 7								
6100	Selling and marketing expenses		57,427	16	53,762	14	170,894	15	170,891	15
6200	General and administrative expenses		53,186	15	48,114	12	158,832	14	150,547	13
6300	Research and development expenses		19,231	5	15,161	4	61,391	6	53,002	4
6450	Expected credit impairment (losses) gains		625	—	54	—	(205)	—	154	—
	Total operating expenses		130,469	36	117,091	30	390,912	35	374,594	32
6900	Income from operations		13,223	4	65,014	17	62,769	6	163,203	14
7000	Non-operating income and expenses									
7050	Finance costs	6(20), 7	(46,531)	(13)	(60,184)	(15)	(161,146)	(14)	(174,499)	(15)
7100	Interest income		4,154	1	22,302	6	28,839	2	67,565	6
7130	Dividend income		37	—	30	—	85,693	8	87,915	8
7190	Other income	7	28,889	8	14,572	4	47,536	4	40,782	3
7225	Gain on disposal of investments		211,447	59	30,640	7	343,077	31	67,399	6
7230	Gain (loss) on foreign exchange		4,715	1	(37,338)	(10)	(62,992)	(6)	37,104	3
7590	Other gains and losses		(135)	—	—	—	(143)	—	(91)	—
7060	Share of profit or loss of associates and joint ventures accounted for using the equity method	6(6)	(28,820)	(8)	(94,064)	(24)	(304,555)	(27)	(271,949)	(23)
7635	Gain (loss) on financial assets and liabilities at fair value through profit or loss		3,067,432	854	472,835	120	2,998,642	268	(311,882)	(27)
	Total non-operating income and expenses		3,241,188	902	348,793	88	2,974,951	266	(457,656)	(39)
7900	Income (loss) before income tax		3,254,411	906	413,807	105	3,037,720	272	(294,453)	(25)
7950	Income tax (expense) benefit	6(22)	(536,817)	(149)	(140,497)	(36)	(497,522)	(45)	(45,408)	(4)
8200	Net income		2,717,594	757	273,310	69	2,540,198	227	(339,861)	(29)

(To be continued)

(Continued)

Account Code	Items	Notes	Three Months Ended September 30				Nine Months Ended September 30			
			2025		2024		2025		2024	
			Amount	%	Amount	%	Amount	%	Amount	%
8300	Other comprehensive income (loss)									
8360	Items that may be reclassified subsequently to profit or loss	6(21)								
8361	Exchange differences arising on translation of foreign operations		55,357	15	8,826	2	(73,637)	(6)	54,178	4
8370	Share of other comprehensive income or loss of associates and joint ventures accounted for using the equity method		5,013	1	(3,077)	(1)	(9,458)	(1)	6,853	1
8399	Income tax (expense) relating to items that may be reclassified to profit or loss	6(22)	(11,404)	(3)	(1,453)	—	15,283	1	(10,843)	(1)
8360	Total components of other comprehensive income that may be reclassified to profit or loss		48,966	13	4,296	1	(67,812)	(6)	50,188	4
8500	Total comprehensive income (loss)		\$ 2,766,560	770	\$ 277,606	70	\$ 2,472,386	221	\$ (289,673)	(25)
8600	Net income (loss) attributable to:									
8610	Shareholders of the parent		\$ 2,717,594	757	\$ 273,310	69	\$ 2,540,198	227	\$ (340,136)	(29)
8620	Non-controlling interests		\$ —	—	\$ —	—	\$ —	—	\$ 275	—
8700	Total comprehensive income attributable to:									
8710	Shareholders of the parent		\$ 2,766,560	770	\$ 277,606	70	\$ 2,472,386	221	\$ (289,948)	(25)
8720	Non-controlling interests		\$ —	—	\$ —	—	\$ —	—	\$ 275	—
9750	Earnings per share Basic earnings (loss) per share	6(23)	\$ 3.80		\$ 0.38		\$ 3.52		\$ (0.48)	
9850	Diluted earnings (loss) per share	6(23)	\$ 3.52		\$ 0.37		\$ 3.32		\$ (0.48)	

(The accompanying notes are an integral part of the consolidated financial statements.)

Center Laboratories, Inc. and Subsidiaries

Consolidated Statements of Changes in Equity

For the nine months ended September 30, 2025 and 2024

In Thousands of New Taiwan Dollars

Items	Equity attributable to shareholders of the parent																		
			Capital surplus			Retained earnings				Other Equity									
	Share capital	Stock dividends to be distributed	Issued at premium	Difference between consideration and carrying amount of subsidiaries acquired or disposed	Changes in net equity of associates and joint ventures accounted for using the equity method	Treasury shares	Others	Stock options	Legal reserve	Special reserve	Unappropriated earnings	Exchange differences arising on translation of foreign operations	Unrealized gain (loss) on financial assets at fair value through other comprehensive income	Total	Treasury shares	Total equity attributable to shareholders of the parent	Non-controlling interests	Total equity	
Balance as of January 1, 2024	\$ 6,914,211	\$ —	\$ 4,866,544	\$ 449,327	\$ 1,046,926	\$ 76,827	\$ 1,540	\$ 800,338	\$ 1,267,810	\$ 5,560,363	\$ (1,004,735)	\$ (50,396)	\$ 74,820	\$ 24,424	\$ (246,721)	\$ 19,756,854	\$ 459,349	\$ 20,216,203	
Issuance of new shares (share exchange)	248,430	—	922,916	(449,327)	—	—	—	—	—	—	(262,401)	—	—	—	—	459,618	(459,618)	—	
Capital surplus used to offset accumulated deficits	—	—	(1,004,735)	—	—	—	—	—	—	—	1,004,735	—	—	—	—	—	—	—	
Cash dividends from capital surplus	—	—	(1,037,159)	—	—	—	—	—	—	—	—	—	—	—	—	(1,037,159)	—	(1,037,159)	
Conversion of convertible bonds to issuance of new shares	87,127	—	306,578	—	—	—	—	—	(75,268)	—	—	—	—	—	—	318,437	—	318,437	
Other changes in capital surplus	—	—	—	—	33,842	—	—	—	—	—	(5,945)	—	—	—	—	27,897	—	27,897	
Adjustments to share of changes in equities of associates	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	69	—	69	
Recovery of unclaimed dividends from shareholders	—	—	—	—	—	—	69	—	—	—	—	—	—	—	—	69	—	69	
Disposal of the parent company's share by subsidiaries recognized as treasury share transactions	—	—	—	—	—	5,115	—	—	—	—	—	—	—	—	37,070	42,185	—	42,185	
Adjustment of capital surplus due to dividends distributed to subsidiary companies	—	—	—	—	—	6,513	—	—	—	—	—	—	—	—	—	6,513	—	6,513	
Net income (loss)	—	—	—	—	—	—	—	—	—	—	(340,136)	—	—	—	—	(340,136)	275	(339,861)	
Other comprehensive income	—	—	—	—	—	—	—	—	—	—	50,188	—	50,188	—	50,188	—	—	50,188	
Balance as of September 30, 2024	\$ 7,249,768	\$ —	\$ 4,054,144	\$ —	\$ 1,080,768	\$ 88,455	\$ 1,609	\$ 725,070	\$ 1,267,810	\$ 5,560,363	\$ (608,482)	\$ (208)	\$ 74,820	\$ 74,612	\$ (209,651)	\$ 19,284,466	\$ 6	\$ 19,284,472	
Balance as of January 1, 2025	\$ 7,249,768	\$ —	\$ 4,054,144	\$ —	\$ 665,876	\$ 88,455	\$ 1,609	\$ 725,873	\$ 1,267,810	\$ 5,560,363	\$ (1,368,634)	\$ (739)	\$ 19,603	\$ 18,864	\$ (209,651)	\$ 18,054,477	\$ 6	\$ 18,054,483	
Cash dividends from capital surplus	—	—	(543,732)	—	—	—	—	—	—	—	—	—	—	—	—	(543,732)	—	(543,732)	
Appropriation of earnings:	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
Stock dividends	—	362,488	—	—	—	—	—	—	—	—	(362,488)	—	—	—	—	—	—	—	
Legal reserve used to offset accumulated deficits	—	—	—	—	—	—	—	—	—	(1,267,810)	—	1,267,810	—	—	—	—	—	—	
Reversal of special reserve	—	—	—	—	—	—	—	—	—	(558,042)	558,042	—	—	—	—	—	—	—	
Other changes in capital surplus	—	—	—	—	—	—	190,292	(190,292)	—	—	—	—	—	—	—	31,949	—	31,949	
Expired stock options	—	—	—	—	—	—	43,434	—	—	—	(11,485)	—	—	—	—	—	—	—	
Adjustments to share of changes in equities of associates	—	—	—	—	—	—	—	—	—	—	(11,485)	—	—	—	—	31,949	—	31,949	
Recovery of unclaimed dividends from shareholders	—	—	—	21	—	—	47	—	—	—	—	—	—	—	—	68	—	68	
Repurchase of treasury shares	—	—	—	—	—	—	—	—	—	—	—	—	—	—	(383,080)	(383,080)	—	(383,080)	
Net income (loss)	—	—	—	—	—	—	—	—	—	—	2,540,198	—	—	—	—	2,540,198	—	2,540,198	
Other comprehensive income	—	—	—	—	—	—	—	—	—	—	(67,812)	—	(67,812)	—	(67,812)	—	(67,812)	—	(67,812)
Share-based compensation	—	—	—	—	—	—	—	5,350	—	—	—	—	—	—	—	5,350	—	5,350	
Balance as of September 30, 2025	\$ 7,249,768	\$ 362,488	\$ 3,510,412	\$ 21	\$ 709,310	\$ 88,455	\$ 191,948	\$ 540,931	\$ —	\$ 5,002,321	\$ 2,623,443	\$ (68,551)	\$ 19,603	\$ (48,948)	\$ (592,731)	\$ 19,637,418	\$ 6	\$ 19,637,424	

(The accompanying notes are an integral part of the consolidated financial statements.)

Center Laboratories, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
For the nine months ended September 30, 2025 and 2024

	In Thousands of New Taiwan Dollars		
	Nine Months Ended September 30		
	2025	2024	
Cash flows from operating activities:			
Profit before income tax	\$ 3,037,720	\$ (294,453)	
Adjustments for:			
The income or loss items which did not affect cash flows			
Depreciation expense	90,598	81,481	
Amortization expense	37,802	37,151	
Share-based compensation	5,350	—	
Loss (gain) on financial assets and liabilities at fair value through profit or loss	(2,998,642)	311,882	
Loss (gain) on disposal of property, plant and equipment	137	(68)	
Expected credit (gains) losses	(205)	154	
Unrealized foreign exchange loss (gain)	7,622	(13,358)	
Interest expense	161,146	174,499	
Interest income	(28,839)	(67,565)	
Dividend income	(85,693)	(87,915)	
Share of profit or loss of associates and joint ventures accounted for using the equity method	304,555	271,949	
Gain on disposal of investments	(343,077)	(67,399)	
Current transfer expenses of construction in process	2,724	—	
Changes in operating assets and liabilities			
Decrease in notes receivable	1,150	33,013	
Decrease in accounts receivable	11,514	17,704	
Decrease in other receivables	573	6,113	
(Increase) in inventories	(17,341)	(29,397)	
(Increase) decrease in other current assets	(1,260)	15,286	
(Increase) in net defined benefit asset/liability	(2,272)	(1,957)	
Decrease) in accounts payable	(27,025)	(30,734)	
Decrease) in other payables	(1,294)	(24,336)	
Decrease) increase in contract liabilities	(9,940)	63,356	
Decrease) increase in other current liabilities	(2,970)	8,977	
Cash generated from operations	<u>142,333</u>	<u>404,383</u>	
Interest received	33,795	73,741	
Interest paid	(49,230)	(69,957)	
Income tax paid	(194,435)	(184,952)	
Net cash (used in) provided by operating activities	<u>(67,537)</u>	<u>223,215</u>	
Cash flows from investing activities:			
Acquisition of financial assets at fair value through profit or loss	(179,032)	(1,359,916)	
Proceeds from disposal of financial assets at fair value through profit or loss	348,929	1,257,540	
Acquisition of investments accounted for using the equity method	(14,612)	(112,550)	
Proceeds from disposal of investments accounted for using the equity method	378,928	90,986	
Acquisition of intangible assets	(2,517)	(3,418)	
Acquisition of property, plant and equipment (Including prepayment for equipment)	(140,425)	(120,326)	
Proceeds from disposal of property, plant and equipment	—	150	
Decrease in financial assets at amortized cost	281,134	758,875	
(Increase) decrease in refundable deposits	(168)	2,067	
Decrease (increase) in other financial assets	889,143	(30,710)	
Dividends received	157,264	96,900	
Net cash provided by investing activities	<u>1,718,644</u>	<u>579,598</u>	

(To be continued)

(Continued)

	Nine Months Ended September 30	
	2025	2024
Cash flows from financing activities:		
(Decrease) increase in short-term loans	(282,000)	962,000
Proceeds from (repayment of) long-term loans	91,699	(650,124)
(Decrease) in guarantee deposits	(2,196)	—
Repayment of convertible bonds at maturity	(1,988,700)	—
Repayment of the principal portion of lease liabilities	(7,129)	(6,872)
Recovery of unclaimed dividends from shareholders	68	69
Cash dividends from capital surplus	—	(1,030,646)
Repurchase of treasury shares	(383,080)	—
Proceeds from disposal of treasury stock	—	42,185
Net cash (used in) financing activities	<u>(2,571,338)</u>	<u>(683,388)</u>
Effect of exchange rate changes on cash and cash equivalents	(528)	504
Net (decrease) increase in cash and cash equivalents	<u>(920,759)</u>	<u>119,929</u>
Cash and cash equivalents, beginning of period	1,442,273	1,704,592
Cash and cash equivalents, end of period	<u>\$ 521,514</u>	<u>\$ 1,824,521</u>

(The accompanying notes are an integral part of the consolidated financial statements.)

Center Laboratories, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
For the Nine Months Ended September 30, 2025 and 2024

(Expressed in New Taiwan Dollars, Unless Specified Otherwise)

1. GENERAL INFORMATION

Center Laboratories, Inc. (hereinafter referred to as “the Company”) was established on November 4, 1959 in accordance with the Company Act. As of September 30, 2025, the Company possessed an authorized capital of \$10,000,000 thousand and a paid-in capital of \$7,249,768 thousand. The Company mainly engages in the manufacture and sale of various Western medicines. The Company and its factories are located in Taipei City and Hsinchu County, Taiwan, respectively.

The Company’s shares have been traded on Taipei Exchange since October 2003.

2. THE AUTHORIZATION OF FINANCIAL STATEMENTS

The consolidated financial statements of the Company have been released after submission to the Board of Directors on November 11, 2025.

3. APPLICATION OF NEW AND REVISED STANDARDS AND INTERPRETATIONS

(1) Initial adoption of the International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), International Financial Reporting Interpretations Committee (IFRIC), and Standard Interpretations Committee (SIC) (hereinafter referred to as the “IFRSs”) endorsed and promulgated by the Financial Supervisory Commission (the “FSC”).

The adoption of the revised IFRSs approved and issued by the Financial Supervisory Commission, effective from January 1, 2025, is not expected to result in significant changes to the accounting policies of the consolidated company.

(2) Applicable IFRSs accredited by FSC in 2026:

New, Revised or Amended Standards and Interpretations	Effective Date of Issuance by the IASB
Annual Improvements to IFRSs - Volume 11	January 1, 2026
Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments”	January 1, 2026
Amendment to IFRS 9 and IFRS 7 “Contracts Referencing Nature-dependent Electricity”	January 1, 2026

(3) IFRSs issued by IASB but not yet accredited by the FSC (actual applicable date shall prevail):

New, Revised or Amended Standards and Interpretations	Effective Date of Issuance by the IASB (Note 1)
Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets between an Investor and its Associate or Joint Venture”	To be determined by IASB.
IFRS 18 “Presentation and Disclosure in Financial Statements”	January 1, 2027
IFRS 19 “Subsidiaries without Public Accountability: Disclosure”	January 1, 2027

Note1: Unless stated otherwise, the aforementioned new, revised and amended standards and interpretations are effective for annual reporting periods beginning on or after the respective effective dates.

In the future, the consolidated company adopts the above IASB standards or interpretations which have not yet been accredited by the FSC and those may have a potential impact on the consolidated company’s financial statements are as follows:

A. IFRS 18 “Presentation and Disclosure in Financial Statements”

IFRS 18 will replace IAS 1 “Presentation of Financial Statements”. The main changes in this standard include:

The income statement should classify revenue and expense items by operating, investing, financing, income tax, and discontinued operations categories.

The income statement should present operating profit or loss, profit or loss before financing and income tax, and subtotals and totals of profit or loss.

Providing guidance to enhance aggregation and disaggregation requirements: Consolidated entities must identify assets, liabilities, equity, income, expenses, and cash flows arising from individual transactions or other events and classify and aggregate them based on common characteristics, ensuring that each significant line item in the primary financial statements has at least one similar characteristic. Items with different characteristics should be disaggregated in the primary financial statements and notes. Consolidated entities should only label such items as “other” when more informative names cannot be found.

Adding disclosures on performance measures defined by management: Consolidated entities should disclose relevant information on performance measures defined by management in a single note to the financial statements when engaging in external communication beyond financial statements and when communicating management’s perspective on a particular aspect of the consolidated entity’s overall financial performance to users of the financial statements. This disclosure should include a description of the measure, how it is calculated, adjustments to subtotals or totals defined in IFRS accounting standards, and the tax and non-controlling interest effects of related adjustments.

As of the date the consolidated financial statements are authorized for issue, the Consolidated Company is continuously assessing the impact of other standards and amendments of interpretation on its financial position and financial performance, and will disclose the relevant impact upon completion of the assessment.

4. SUMMARY OF MATERIAL ACCOUNTING POLICIES

Apart from the following explanation, the significant accounting policies adopted in this consolidated financial report are consistent with those of the 2024 consolidated financial report. For further information, please refer to Note 4 of the 2024 consolidated financial report.

(1) Statement of Compliance

This consolidated financial statements have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers (hereinafter referred to as the “Regulations”) and IAS 34 “Interim Financial Reporting” as recognized and issued by the Financial Supervisory Commission. This consolidated financial report does not include all the necessary information required to be disclosed in the entire annual consolidated financial statements prepared in accordance with the International Financial Reporting Standards, International Accounting Standards, Interpretations, and Interpretation Bulletins as recognized and issued by the Financial Supervisory Commission.

(2) Basis of Preparation

Except for financial instruments measured by fair value, the consolidated financial statements are prepared on a historical cost basis. Historical cost is usually based on the fair value of the consideration paid to acquire the asset.

(3) Basis of Preparation for Consolidated Financial Statements

The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company (its subsidiaries). Control refers to the Company’s power to direct the financial and operating policies of an individual to obtain benefits from its related operating activities.

The consolidated income statement has Income and expenses of subsidiaries acquired or disposed of are included in the consolidated statement of comprehensive income from the effective date of acquisition and up to the effective date of disposal, as appropriate. The total comprehensive income of subsidiaries is attributed to the Company’s shareholders and non-controlling interests, even if this results in non-controlling interests having a deficit balance.

When necessary, adjustments are made to subsidiaries' financial statements to bring their accounting policies into line with those used by the Company.

All significant transactions, balances, income, and expenses between the Company's consolidated entities are eliminated in full on consolidation.

Changes in the Company's ownership interests in subsidiaries that do not result in the Company losing control over the subsidiaries are accounted for as equity transactions. The carrying amounts of the Company's interests and the non-controlling interests are adjusted to reflect changes in their relative interests in the subsidiaries. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to the Company's shareholders.

When the consolidated company loses control of the subsidiary, the disposition gains and losses are the difference between the following two; (1) The fair value of the consideration received and the remaining investment in the former subsidiary is counted at the fair value on the day when the control was lost, and (2) The assets (including goodwill), liabilities, and non-controlling interests of the former subsidiary are counted based on the book value on the date of loss of control. The consolidated company recognizes all amounts related to the subsidiary in other comprehensive profits and losses, and its accounting treatment is based on the same basis that the consolidated company must follow when directly processing related assets or liabilities.

The former subsidiary's remaining investment is based on the fair value at the date of loss of control as the amount initially recognized for investment in the affiliated Company.

A. The subsidiaries included in the preparation of the consolidated financial statements are listed as follows:

Name of Investor	Name of Subsidiary	Relationship with the Company	Nature of Business	Percentage of Ownership/Capital Contribution		
				September 30, 2025	December 31, 2024	September 30, 2024
The Company	Center Biotherapeutics Inc.	A subsidiary of the Company	Investment	100.00%	100.00%	100.00%
The Company	Centerlab Investment Holding Limited	A subsidiary of the Company	Investment	100.00%	100.00%	100.00%
The Company	BioEngine Technology Development Inc.	A subsidiary of the Company	Investment	100.00%	100.00%	100.00%
The Company and Centerlab Investment Holding Limited	Bioflag International Corporation	A subsidiary of the Company	Investment	100.00%	100.00%	100.00%
Bioflag International Corporation	Bioflag Co., Ltd.	Sub-subsidiary of the Company	Investment	—	100.00%	100.00%
Bioflag International Corporation	Glac Biotech Co., Ltd.	Sub-subsidiary of the Company	Manufacturing and Sales of Functional Probiotics	100.00%	—	—

Name of Investor	Name of Subsidiary	Relationship with the Company	Nature of Business	Percentage of Ownership/Capital Contribution		
				September 30, 2025	December 31, 2024	September 30, 2024
Bioflag Co., Ltd.	Genlac Biotech Inc.	Sub-subsidiary of the Company	Investment	—	—	100.00%
Bioflag Co., Ltd. or Genlac Biotech Inc.	Glac Biotech Co., Ltd.	Sub-subsidiary of the Company	Manufacturing and Sales of Functional Probiotics	—	100.00%	100.00%
Glac Biotech Co., Ltd.	OmniPro Biotech Co., Ltd.	Sub-subsidiary of the Company	General Food Manufacturing	100.00%	100.00%	100.00%
Glac Biotech Co., Ltd.	Ezadd Co., Ltd.	Sub-subsidiary of the Company	Functional Probiotics Sales	99.50%	99.50%	99.50%
The Company	Center Laboratories Limited	A subsidiary of the Company	Investment	100.00%	100.00%	100.00%
The Company	Center Venture Holding I Limited	A subsidiary of the Company	Investment	100.00%	100.00%	100.00%
The Company	Center Venture Holding II Limited	A subsidiary of the Company	Investment	100.00%	100.00%	100.00%
The Company	Center Venture Holding III Limited	A subsidiary of the Company	Investment	100.00%	100.00%	100.00%
BioEngine Technology Development Inc.	BioEngine Development I Limited	Sub-subsidiary of the Company	Investment	100.00%	100.00%	100.00%
BioEngine Development I Limited	Beijing Shundu Pharmaceutical Research Institute Co., Ltd.	Sub-subsidiary of the Company	Research and Development of New Pharmaceuticals and Skincare Products	100.00%	100.00%	100.00%

B. The important changes in the consolidated entities are explained as follows:

- (a) In May 2024, the Company acquired 52.67% of the shares of Bioflag International Corporation through the issuance of new shares. After the share exchange, Bioflag International Corporation became a wholly-owned subsidiary of the Company.
- (b) Genlac Biotech Inc. was dissolved in September 2024 and completed its liquidation in November of the same year. Its original investment in Glac Biotech Co., Ltd. is now directly held by Bioflag Co., Ltd.
- (c) Bioflag Co., Ltd. completed its dissolution and liquidation procedures in May 2025. The investment originally held by Glac Biotech Co., Ltd. is now directly held by Bioflag International Corporation.

(4) Income Tax

The Group measures and discloses income tax expense for interim periods in accordance with paragraph B12 of IAS 34 “Interim Financial Reporting”.

Income tax expense is measured by applying the best estimate of the applicable tax rate for the expected annual total earnings of the management multiplied by the pre-tax net profit for the interim reporting period, and is fully recognized as the current income tax expense.

Income tax expense that is directly recognized in equity items or other comprehensive income items is measured based on the temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and their tax bases, using the applicable tax rates expected to be realized or settled upon.

(5) Defined benefit post-employment benefits

Pension cost for the interim period is calculated on a year-to-date basis using the actuarially determined pension cost rate as of the prior year-end date, adjusted for significant market fluctuations during the period and significant plan amendments, settlements or other significant one-time events.

5. MATERIAL ACCOUNTING JUDGMENTS AND KEY SOURCES OF ESTIMATION AND UNCERTAINTY

The preparation of these consolidated financial statements in conformity with the Regulations and IAS 34, “Interim Financial Reporting,” as endorsed by the FSC, requires management to make judgments, estimates and assumptions that affect the adoption of accounting policies and the reported amounts of assets, liabilities, revenues and expenses. Actual results may differ from the estimates.

Estimates and fundamental assumptions are regularly reviewed. If a revision of the estimate only impacts the current period, it is reflected in the accounting estimate revision for that period. If the revision of the accounting estimate affects both the current period and future periods, it is reflected in the estimate revision for both the current and future periods.

When preparing the consolidated financial statements, the significant judgments made by management in the adoption of accounting policies for consolidation and the principal sources of estimation uncertainty are consistent with Note 5 of the 2024 consolidated financial statements.

6. DESCRIPTION OF SIGNIFICANT ACCOUNTS

(1) Cash and cash equivalents

Items	September 30,	December 31,	September 30,
	2025	2024	2024
Cash on hand and petty cash	\$ 479	\$ 505	\$ 508
Checking accounts and demand deposits	360,868	798,046	755,272
Cash equivalents:			
Time deposits	160,167	643,722	1,068,741
Total	\$ 521,514	\$ 1,442,273	\$ 1,824,521

- A. Equivalent cash includes time deposits that are highly liquid, convertible into fixed cash at any time and have little risk of price changes within 3 months from the date of acquisition, and are used to meet short-term cash commitments.
- B. Cash and cash equivalents described above have not been pledged as collateral.

(2) Financial instruments at fair value through profit or loss

Items	September 30, 2025	December 31, 2024	September 30, 2024
Financial assets - current			
Designated to be measured at fair value through profit or loss			
Foreign listed stocks	\$ 497,211	\$ 257,998	\$ 320,402
Financial assets - non-current			
Designated to be measured at fair value through profit or loss			
Domestic listed stocks	\$ 2,459,193	\$ 2,567,288	\$ 2,949,924
Domestic unlisted ordinary shares and emerging stocks	208,057	192,667	181,071
Foreign listed stocks	4,272,477	1,351,278	1,741,421
Equity shares of unlisted foreign companies	1,034,728	1,060,446	1,063,555
Foreign unlisted preference/ordinary shares	3,084,612	3,439,016	3,249,801
Foreign funds	4,577,893	4,434,912	4,321,663
Hybrid financial assets	5,339	—	—
Derivative financial instruments - redemption rights	1,470	3,117	3,467
Total	<u>\$ 15,643,769</u>	<u>\$ 13,048,724</u>	<u>\$ 13,510,902</u>
Financial liabilities - non-current			
Designated to be measured at fair value through profit or loss			
Derivative financial instruments - put options	\$ 53,568	\$ 46,158	\$ 31,945

- A. The Company has issued convertible corporate bonds, which consist of principal contract debt instruments and put option derivative instruments. Put option derivatives are valued at fair value and reported as profit or loss.
- B. Please refer to Note 8 for the details that the Company provides financial assets as collateral for bank loans.

(3) Financial assets at amortized cost

Item	September 30, 2025	December 31, 2024	September 30, 2024
Current item:			
Time deposits with original maturity period of more than three months	\$ 61,253	\$ 350,009	\$ —

A. The ranges of market interest rates on time deposits at the balance sheet date are listed as follows:

Item	September 30, 2025	December 31, 2024	September 30, 2024
Time deposits	1.47%~3.20%	3.0%~4.57%	—

(4) Accounts receivable, net

Items	September 30, 2025	December 31, 2024	September 30, 2024
Measured at amortized cost			
Accounts receivable			
from general customers	\$ 168,841	\$ 180,354	\$ 174,410
Less: Loss allowance	(1,863)	(1,775)	(1,668)
Net	\$ 166,978	\$ 178,579	\$ 172,742

None of the accounts receivable above has been pledged as collateral.

The consolidated company estimates expected credit losses for all accounts receivable using a simplified approach, i.e. measurement of lifetime expected credit losses. For the purpose of measurement, expected credit loss rate is determined based on the number of days on which an account receivable is recorded, and is included in forward-looking information. The analysis of expected credit losses for accounts receivable as of September 30, 2025, December 31, 2024, and September 30, 2024, is as follows:

September 30, 2025

Age	Carrying Amount of Accounts Receivable	Allowance for Lifetime Expected Credit Losses
Within 90 days	\$ 143,353	\$ 459
90 days to 180 days	23,609	450
180 days to 365 days	1,561	636
Over 365 days	318	318
Total	\$ 168,841	\$ 1,863

December 31, 2024

Age	Carrying Amount of Accounts Receivable	Allowance for Lifetime Expected Credit Losses
Within 90 days	\$ 158,465	\$ 408
90 days to 180 days	20,289	370
180 days to 365 days	1,281	678
Over 365 days	319	319
Total	\$ 180,354	\$ 1,775

September 30, 2024

Age	Carrying Amount of Accounts Receivable	Allowance for Lifetime Expected Credit Losses
Within 90 days	\$ 151,144	\$ 361
90 days to 180 days	21,579	408
180 days to 365 days	1,304	685
Over 365 days	383	214
Total	\$ 174,410	\$ 1,668

Information on changes in allowance for bad debt arising from accounts receivable is listed as follows:

Items	September 30, 2025	September 30, 2024
Beginning balance	\$ 1,775	\$ 1,953
Recognition of impairment loss	88	170
Written-off as uncollectible	—	(455)
Ending balance	\$ 1,863	\$ 1,668

(5) Inventories

Items	September 30, 2025	December 31, 2024	September 30, 2024
Merchandise inventories	\$ 309	\$ 389	\$ 148
Finished goods	185,730	156,365	169,422
Work-in-progress and semi-finished goods	49,267	44,745	40,240
Raw materials	100,770	103,046	93,972
Supplies	11,618	12,194	20,837
Inventories in transit	5,668	19,236	1,498
Total	\$ 353,362	\$ 335,975	\$ 326,117
Less: Allowance for inventory valuation losses	(26,318)	(26,272)	(27,492)
Net	\$ 327,044	\$ 309,703	\$ 298,625

Costs of goods sold for the nine months ended September 30, 2025 and 2024 include inventory valuation losses (reversal of write-down of inventory) amounting to \$1,760 thousand and \$4,396 thousand, respectively.

(6) Investments accounted for using the equity method

Item	September 30, 2025	December 31, 2024	September 30, 2024
Investments in associates	\$ 5,312,120	\$ 5,761,850	\$ 5,769,286

A. Investments in associates are detailed as follows:

Items	September 30, 2025	December 31, 2024	September 30, 2024
Material associates			
Medeon Biodesign, Inc.	\$ 309,405	\$ 452,226	\$ 511,616
TOT BIOPHARM International Company Limited	2,916,284	2,983,726	2,995,726
Mycenax Biotech Inc.	347,176	426,073	442,036
Lumosa Therapeutics Co., Ltd.	559,650	668,841	388,627
	4,132,515	4,530,866	4,338,005
Individually immaterial associates	1,179,605	1,230,984	1,431,281
Total	\$ 5,312,120	\$ 5,761,850	\$ 5,769,286

B. The basic information of associates that are material to the Group is listed as follows:

Items	Shareholding percentage		
	September 30, 2025	December 31, 2024	September 30, 2024
Medeon Biodesign, Inc.	26.37%	29.75%	29.75%
TOT BIOPHARM International Company Limited	28.59%	28.59%	28.59%
Mycenax Biotech Inc.	20.64%	20.65%	20.69%
Lumosa Therapeutics Co., Ltd.	34.97%	34.83%	33.41%

For information on the nature of business, principal place of business, and country of registration of the associates above, please refer to Table 2 “Information on Investees” and Table 3 “Information on Investment in Mainland China.”

C. Information on the Level 1 fair value measurements of associates with quoted prices in active markets is provided as follows:

	September 30, 2025	December 31, 2024	September 30, 2024
Medeon Biodesign, Inc.	\$ 2,233,313	\$ 1,086,847	\$ 1,267,760
TOT BIOPHARM International Company Limited	1,945,370	1,669,864	1,800,808
Mycenax Biotech Inc.	606,225	693,285	792,326
Lumosa Therapeutics Co., Ltd.	12,035,381	10,407,523	12,545,496
Individually immaterial associates	1,557,691	1,264,567	1,439,314
Total	\$ 18,377,980	\$ 15,122,086	\$ 17,845,704

D. For the amount of investments in associates pledged by the Company as collateral for borrowings, please refer to Note 8.

E. The summary financial information of the material associates below is provided according to the consolidated financial statements of each associate prepared based on IFRSs, and has reflected adjustments made thereto using the equity method.

Balance Sheets

	September 30, 2025			
	Medeon Biodesign, Inc.	TOT BIOPHARM International Company Limited	Mycenax Biotech Inc.	Lumosa Therapeutics Co., Ltd.
Current assets	\$ 1,041,322	\$ 2,799,939	\$ 804,746	\$ 1,015,683
Non-current assets	478,237	3,592,349	2,524,281	716,945
Current liabilities	174,263	1,136,291	1,079,900	128,342
Non-current liabilities	94,286	1,642,332	606,559	1,744
Equity	1,251,010	3,613,665	1,642,568	1,602,542
Non-controlling interests	(77,602)	—	—	(11,131)
	<u>\$ 1,173,408</u>	<u>\$ 3,613,665</u>	<u>\$ 1,642,568</u>	<u>\$ 1,591,411</u>
 The Company's share of profit	 \$ 309,405	 \$ 1,033,231	 \$ 338,927	 \$ 556,580
Goodwill	—	1,883,053	8,249	11,031
Downstream/sidestream transactions with associates	—	—	—	(7,961)
Carrying amount of associates invested	<u>\$ 309,405</u>	<u>\$ 2,916,284</u>	<u>\$ 347,176</u>	<u>\$ 559,650</u>
	December 31, 2024			
	Medeon Biodesign, Inc.	TOT BIOPHARM International Company Limited	Mycenax Biotech Inc.	Lumosa Therapeutics Co., Ltd.
Current assets	\$ 1,317,199	\$ 3,328,394	\$ 736,381	\$ 1,537,047
Non-current assets	560,544	4,010,027	2,631,995	595,914
Current liabilities	215,642	1,859,996	661,496	201,176
Non-current liabilities	126,198	1,628,890	683,401	4,281
Equity	1,535,903	3,849,535	2,023,479	1,927,504
Non-controlling interests	(15,711)	—	—	(15,835)
	<u>\$ 1,520,192</u>	<u>\$ 3,849,535</u>	<u>\$ 2,023,479</u>	<u>\$ 1,911,669</u>
 The Company's share of profit	 \$ 452,226	 \$ 1,100,673	 \$ 417,824	 \$ 665,886
Goodwill	—	1,883,053	8,249	11,031
Downstream/sidestream transactions with associates	—	—	—	(8,076)
Carrying amount of associates invested	<u>\$ 452,226</u>	<u>\$ 2,983,726</u>	<u>\$ 426,073</u>	<u>\$ 668,841</u>

September 30, 2024

	Medeon Biodesign, Inc.	TOT BIOPHARM International Company Limited	Mycenax Biotech Inc.	Lumosa Therapeutics Co., Ltd.
Current assets	\$ 1,525,842	\$ 3,451,406	\$ 827,836	\$ 733,535
Non-current assets	559,365	3,922,747	2,649,930	643,016
Current liabilities	193,901	1,804,374	644,103	195,903
Non-current liabilities	139,345	1,676,323	737,018	5,338
Equity	1,751,961	3,893,456	2,096,645	1,175,310
Non-controlling interests	(32,127)	—	—	(20,881)
	<u>\$ 1,719,834</u>	<u>\$ 3,893,456</u>	<u>\$ 2,096,645</u>	<u>\$ 1,154,429</u>
The Company's share of profit	\$ 511,616	\$ 1,112,673	\$ 433,787	\$ 385,707
Goodwill	—	1,883,053	8,249	11,031
Downstream/sidestream transactions with associates	—	—	—	(8,111)
Carrying amount of associates invested	\$ 511,616	\$ 2,995,726	\$ 442,036	\$ 388,627
	<u>\$ 511,616</u>	<u>\$ 2,995,726</u>	<u>\$ 442,036</u>	<u>\$ 388,627</u>

Statements of Comprehensive Income

Three Months Ended September 30, 2025

	Medeon Biodesign, Inc.	TOT BIOPHARM International Company Limited	Mycenax Biotech Inc.	Lumosa Therapeutics Co., Ltd.
Revenue	\$ 92,295	\$ 542,625	\$ 131,371	\$ 11,075
Net income of continuing operations	\$ (185,999)	\$ (32,527)	\$ (129,879)	\$ (34,233)
Other comprehensive income (net after tax)	10,037	5,802	162	51
Total comprehensive income (loss)	\$ (175,962)	\$ (26,725)	\$ (129,717)	\$ (34,182)
Dividends received from associates	\$ —	\$ —	\$ —	\$ —
	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>

Nine Months Ended September 30, 2025

	Medeon Biodesign, Inc.	TOT BIOPHARM International Company Limited	Mycenax Biotech Inc.	Lumosa Therapeutics Co., Ltd.
Revenue	\$ 304,555	\$ 2,697,923	\$ 455,646	\$ 22,781
Net income of continuing operations	\$ (564,849)	\$ (14,629)	\$ (396,178)	\$ (289,614)
Other comprehensive income (net after tax)	(24,867)	(9,730)	(338)	(61)
Total comprehensive income (loss)	\$ (589,716)	\$ (24,359)	\$ (396,516)	\$ (289,675)
Dividends received from associates	\$ —	\$ —	\$ —	\$ —
	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>

Three Months Ended September 30, 2024

	Medeon Biodesign, Inc.	TOT BIOPHARM International Company Limited	Mycenax Biotech Inc.	Lumosa Therapeutics Co., Ltd.
Revenue	\$ 104,793	\$ 1,300,012	\$ 209,130	\$ 6,369
Net income of continuing operations	\$ (201,553)	\$ 18,161	\$ (146,612)	\$ (231,338)
Other comprehensive income (net after tax)	(6,655)	(5,084)	(176)	24
Total comprehensive income (loss)	\$ (208,208)	\$ 13,077	\$ (146,788)	\$ (231,314)
Dividends received from associates	\$ —	\$ —	\$ —	\$ —

Nine Months Ended September 30, 2024

	Medeon Biodesign, Inc.	TOT BIOPHARM International Company Limited	Mycenax Biotech Inc.	Lumosa Therapeutics Co., Ltd.
Revenue	\$ 215,460	\$ 3,597,069	\$ 489,931	\$ 19,348
Net income of continuing operations	\$ (644,829)	\$ 157,409	\$ (383,839)	\$ (283,294)
Other comprehensive income (net after tax)	11,979	1,636	53	61
Total comprehensive income (loss)	\$ (632,850)	\$ 159,045	\$ (383,786)	\$ (283,233)
Dividends received from associates	\$ —	\$ —	\$ —	\$ —

F. The carrying amounts and share of operating results of the Group's individually immaterial associates are summarized as follows:

As of September 30, 2025, December 31, 2024, and September 30, 2024, the aggregate carrying amounts of other affiliated companies within the Group were \$1,179,605 thousand, \$1,230,984 thousand, and \$1,431,281 thousand, respectively.

The Company's share of profit	Three Months Ended September 30	
	2025	2024

Net income of continuing operations	\$ 70,523	\$ 65,725
Other comprehensive income (net after tax)	\$ 815	\$ 300

The Company's share of profit	Nine Months Ended September 30	
	2025	2024

Net income of continuing operations	\$ 46,534	\$ 43,450
Other comprehensive income (net after tax)	\$ 772	\$ 2,905

(7) Property, plant and equipment

A. The carrying amounts of the Group's property, plant, and equipment are listed as follows:

Items	September 30, 2025	December 31, 2024	September 30, 2024
Land, buildings, and facilities	\$ 782,014	\$ 775,110	\$ 780,865
Machinery and equipment	424,213	379,542	378,562
Transportation equipment	1,341	1,727	1,870
Office equipment	49,365	54,066	42,251
Leasehold improvements	114,886	100,899	105,867
Miscellaneous equipment	37,824	27,808	28,857
Construction in progress and equipment under installation	61,320	76,768	33,786
Total	\$ 1,470,963	\$ 1,415,920	\$ 1,372,058

B. Changes in cost, depreciation, and impairment loss on the Group's property, plant, and equipment are detailed as follows:

	Balance as of January 1, 2025	Additions - individually acquired	Disposals	Reclassification	Effect of exchange differences	Balance as of September 30, 2025
Cost:						
Land, buildings, and facilities	\$ 1,016,898	\$ 10,840	\$ —	\$ 13,792	\$ —	\$ 1,041,530
Machinery and equipment	748,006	32,098	(4,877)	49,517	(32)	824,712
Transportation equipment	5,716	—	—	—	—	5,716
Office equipment	156,525	4,044	(2,021)	378	—	158,926
Leasehold improvements	137,863	3,123	—	23,749	—	164,735
Miscellaneous equipment	60,245	2,797	(1,099)	10,912	—	72,855
Construction in progress and equipment under installation	76,768	66,698	—	(82,146)	—	61,320
Total	\$ 2,202,021	\$ 119,600	\$ (7,997)	\$ 16,202	\$ (32)	\$ 2,329,794
	Balance as of January 1, 2025	Depreciation	Disposals	Reclassification	Effect of exchange differences	Balance as of September 30, 2025
Accumulated Depreciation and Impairment:						
Buildings and facilities	\$ 241,788	\$ 17,728	\$ —	\$ —	\$ —	\$ 259,516
Machinery and equipment	368,464	36,807	(4,741)	—	(31)	400,499
Transportation equipment	3,989	386	—	—	—	4,375
Office equipment	102,459	9,122	(2,020)	—	—	109,561
Leasehold improvements	36,964	12,885	—	—	—	49,849
Miscellaneous equipment	32,437	3,693	(1,099)	—	—	35,031
Total	\$ 786,101	\$ 80,621	\$ (7,860)	\$ —	\$ (31)	\$ 858,831

	Balance as of January 1, 2024	Additions - individually acquired	Disposals	Reclassification	Effect of exchange differences	Balance as of September 30, 2024
Cost:						
Land, buildings, and facilities	\$ 997,954	\$ 968	\$ —	\$ 17,976	\$ —	\$ 1,016,898
Machinery and equipment	675,454	40,512	(147)	30,477	30	746,326
Transportation equipment	6,206	959	(1,448)	—	—	5,717
Office equipment	137,524	4,439	(57)	390	—	142,296
Leasehold improvements	129,659	7,442	—	762	—	137,863
Miscellaneous equipment	53,348	7,201	(304)	—	—	60,245
Construction in progress and equipment under installation	46,264	37,127	—	(49,605)	—	33,786
Total	\$ 2,046,409	\$ 98,648	\$ (1,956)	\$ —	\$ 30	\$ 2,143,131
Accumulated Depreciation and Impairment:						
Buildings and facilities	\$ 219,630	\$ 16,403	\$ —	\$ —	\$ —	\$ 236,033
Machinery and equipment	334,973	32,907	(143)	—	27	367,764
Transportation equipment	4,898	336	(1,387)	—	—	3,847
Office equipment	91,441	8,656	(52)	—	—	100,045
Leasehold improvements	21,853	10,143	—	—	—	31,996
Miscellaneous equipment	28,842	2,838	(292)	—	—	31,388
Total	\$ 701,637	\$ 71,283	\$ (1,874)	\$ —	\$ 27	\$ 771,073

- C. The amount of capitalized interest for the nine months ended September 30, 2025 and 2024 in the consolidated company was both 0 thousand dollars.
- D. Please refer to Note 8 for the amount of property, plant, and equipment set by the consolidated company as collateral for a loan.

(8) Lease agreements

A. Right-of-use assets

	September 30, 2025	December 31, 2024	September 30, 2024
The carrying amount of right-of-use assets			
Buildings and facilities	\$ 10,269	\$ 15,779	\$ 17,835
Transportation equipment	569	1,301	1,545
Total	\$ 10,838	\$ 17,080	\$ 19,380

	Nine Months Ended September 30	
	2025	2024
	\$	\$
Additions to right-of-use assets	709	—
Depreciation of right-of-use assets		
Buildings and facilities	6,219	6,168
Transportation equipment	732	732
Total	6,951	6,900

B. Lease liabilities

	September 30, 2025	December 31, 2024	September 30, 2024
Current	\$ 9,230	\$ 9,214	\$ 9,228
Non-current	\$ 1,737	\$ 8,173	\$ 10,469

The ranges of discount rates for lease liabilities are listed as follows:

	September 30, 2025	December 31, 2024	September 30, 2024
Buildings and facilities	1.350%	1.350%	1.350%
Transportation equipment	2.072%	2.072%	2.072%

C. Other lease information:

	Three Months Ended September 30		Nine Months Ended September 30	
	2025	2024	2025	2024
Short-term lease and low-value asset expenses	\$ 329	\$ 728	\$ 1,066	\$ 2,167
Total cash outflow for leases			\$ (7,129)	\$ (6,872)

The consolidated company chooses to exempt the leases applicable to leases such as housing eligible for short-term leases and certain office equipment, such as low-value assets and does not recognize the relevant right of use assets and lease liabilities for such tenancies.

D. Operating leasing commitment - the consolidated company as a lessor

The consolidated company leases offices and factories by means of operating lease. The future minimum lease payments under non-cancellable operating leases as of September 30, 2025, and 2024 were listed as follows:

Items	September 30, 2025	September 30, 2024
Less than 1 year	\$ 10,750	\$ 29,372
More than 1 year but less than 5 years	4,950	48,513
Total	\$ 15,700	\$ 77,885

(9) Investment property

A. The carrying amounts of the consolidated company's investment property are listed as follows:

Items	September 30, 2025	December 31, 2024	September 30, 2024
Land	\$ 557,177	\$ 557,177	\$ 557,177
Buildings and facilities	102,044	105,070	106,084
Total	\$ 659,221	\$ 662,247	\$ 663,261

B. Changes in costs, depreciation, and impairment loss on the Group's investment property are detailed as follows:

Cost	Land	Buildings and facilities	Total
Balance as of January 1, 2025	\$ 557,177	\$ 151,867	\$ 709,044
Additions	—	—	—
Balance as of September 30, 2025	\$ 557,177	\$ 151,867	\$ 709,044
Accumulated Depreciation and Impairment			
Balance as of January 1, 2025	\$ —	\$ 46,797	\$ 46,797
Depreciation	—	3,026	3,026
Balance as of September 30, 2025	\$ —	\$ 49,823	\$ 49,823

Cost	Land	Buildings and facilities	Total
Balance as of January 1, 2024	\$ 557,177	\$ 151,867	\$ 709,044
Additions	—	—	—
Balance as of September 30, 2024	\$ 557,177	\$ 151,867	\$ 709,044
Accumulated Depreciation and Impairment			
Balance as of January 1, 2024	\$ —	\$ 42,485	\$ 42,485
Depreciation	—	3,298	3,298
Balance as of September 30, 2024	\$ —	\$ 45,783	\$ 45,783

C. As of September 30, 2025 and 2024, the fair values of the investment properties held by the consolidated company were NT\$859,365 thousand and NT\$822,219 thousand, respectively. The merged company's investment real estate is to appoint an independent external appraisal expert to evaluate the fair value. The fair value is estimated based on market evidence of similar real estate transaction prices.

D. The rental income generated from investment properties for the periods July 1 to September 30, 2025 and 2024 and from January 1 to September 30, 2025 and 2024 were NT\$3,458 thousand, NT\$8,258 thousand, NT\$13,728 thousand and NT\$24,646 thousand, respectively. There were no direct operating expenses incurred from January 1 to September 30, 2025 and 2024.

E. For investment property pledged by the Group, please refer to Note 8.

(10) Intangible assets

A. The carrying amounts of the Group's intangible assets are listed as follows:

Items	September 30, 2025	December 31, 2024	September 30, 2024
Computer software	\$ 5,018	\$ 4,956	\$ 4,933
Goodwill	398,359	398,359	398,359
Proprietary technology	151,136	166,770	171,981
Trademark rights	190,549	210,262	216,833
Total	\$ 745,062	\$ 780,347	\$ 792,106

B. The consolidated company's changes in costs, amortizations and impairment losses of the intangible assets are detailed as follows:

	Balance as of January 1, 2025	Additions - individually acquired	Disposals	Balance as of September 30, 2025
Cost:				
Computer software	\$ 22,629	\$ 2,517	\$ —	\$ 25,146
Goodwill	398,359	—	—	398,359
Proprietary technology	208,462	—	—	208,462
Trademark rights	262,828	—	—	262,828
Total	\$ 892,278	\$ 2,517	\$ —	\$ 894,795
	Balance as of January 1, 2025	Amortization	Disposals	Balance as of September 30, 2025
Accumulated amortization and impairment:				
Computer software	\$ 17,673	\$ 2,455	\$ —	\$ 20,128
Proprietary technology	41,692	15,634	—	57,326
Trademark rights	52,566	19,713	—	72,279
Total	\$ 111,931	\$ 37,802	\$ —	\$ 149,733

	Balance as of January 1, 2024	Additions - individually acquired	Disposals	Balance as of September 30, 2024
Cost:				
Computer software	\$ 18,309	\$ 3,418	\$ —	\$ 21,727
Goodwill	398,359	—	—	398,359
Proprietary technology	208,462	—	—	208,462
Trademark rights	262,828	—	—	262,828
Total	\$ 887,958	\$ 3,418	\$ —	\$ 891,376
	Balance as of January 1, 2024	Amortization	Disposals	Balance as of September 30, 2024
Accumulated amortization and impairment:				
Computer software	\$ 14,990	\$ 1,804	\$ —	\$ 16,794
Proprietary technology	20,846	15,635	—	36,481
Trademark rights	26,283	19,712	—	45,995
Total	\$ 62,119	\$ 37,151	\$ —	\$ 99,270

- C. No impairment losses on goodwill were recognized for the nine months ended September 30, 2025 and 2024 in the consolidated company.
- D. Amortization expense that should be recognized in the Group's intangible assets has been included in operating costs and operating expenses provided in the consolidated statements of profit and loss.

(11) Loans

A. Short-term loans

	September 30, 2025	December 31, 2024	September 30, 2024
Bank loans			
Unsecured loans	\$ 430,000	\$ 500,000	\$ —
Secured loans	550,000	762,000	1,292,000
Total	\$ 980,000	\$ 1,262,000	\$ 1,292,000
Range of interest rates	2.18%~2.65%	2.10%~2.60%	1.90%~3.07%

B. Long-term loans

	September 30, 2025	December 31, 2024	September 30, 2024
Bank loans			
Secured loans	\$ 1,152,820	\$ 1,061,121	\$ 263,858
Less: current portion	(36,785)	(641,123)	(41,038)
Total	\$ 1,116,035	\$ 419,998	\$ 222,820

- C. For assets pledged by the Group as collateral for long-term borrowings, please refer to Note 8.
- D. For details of the consolidated company's interest rate, foreign currency, and liquidity risk, please refer to Note 6(26).

(12) Other payables

Items	September 30, 2025	December 31, 2024	September 30, 2024
Accrued expenses			
Salaries, bonuses and employee social insurance	\$ 71,891	\$ 80,381	\$ 62,624
Employee Bonuses and Directors' Remuneration	12,085	—	—
Commission expense	2,890	3,497	2,782
Other accrued expenses	51,031	49,796	46,708
Subtotal	137,897	133,674	112,114
Business tax payable	2,517	7,578	2,517
Equipment payables	10,712	14,715	16,579
Dividends payable	543,732	—	—
Total	\$ 694,858	\$ 155,967	\$ 131,210

(13) Bonds payable

	September 30, 2025	December 31, 2024	September 30, 2024
Domestic unsecured convertible bonds	\$ 1,944,300	\$ 1,944,300	\$ 1,944,300
Domestic secured convertible bonds	636,200	2,624,900	2,624,900
Less: Discounts on bonds payable	(271,943)	(379,579)	(416,018)
Less: current portion	(1,713,575)	(1,954,704)	(1,942,179)
Total	\$ 594,982	\$ 2,234,917	\$ 2,211,003

Changes from January 1 to September 30, 2025 and 2024:

Items	September 30, 2025	September 30, 2024
Liability component on January 1	\$ 4,189,621	\$ 4,350,826
Interest calculated using the effective interest rate	107,636	115,332
Less: Issuance of ordinary shares of convertible bonds	—	(312,976)
Less: Repayment of convertible bonds at maturity	(1,988,700)	—
Less: current portin	(1,713,575)	(1,942,179)
Liability component on September 30	\$ 594,982	\$ 2,211,003

A. Fourth Domestic Secured Convertible Bonds

On September 7, 2020, the Company issued 5,000 units of New Taiwan Dollar-denominated zero-coupon secured convertible bonds totaling NT\$500,000 thousand.

Each unit bondholder has the right to convert their bonds into ordinary shares of the Company at a rate of NT\$91 per share. The conversion period for the convertible bonds is three months from the date when the convertible bonds were issued to the maturity date. On the third anniversary of the issuance of the convertible bonds, bondholders can request the Company to redeem their bonds in cash at 100.75% of the face value plus accrued interest, resulting in an effective yield 0.25%.

The convertible bonds consist of both debt and equity components, with the equity component being represented as capital surplus - stock options under equity items. The original recognized effective interest rate for the debt component is 1.0452%.

The amount of unconverted bonds due for repayment on September 7, 2025 was \$498,600 thousand. At the same time, \$22,428 thousand worth of convertibles whose conversion option has lapsed will be transferred from capital surplus - stock options to capital surplus - others.

During the issuance of the convertible bonds, the conversion option of the bonds was separated from liabilities. Information on the recognition of the convertible bonds in equity and liabilities is provided as follows:

The present value of the compound interest on convertible corporate bonds	\$	474,668
Embedded derivative instrument - the right of redemption and put-back		1,530
Equity component at issuance		22,491
Issue price of convertible bonds (net of issuance costs of NT\$1,311 thousand)	\$	498,689

B. Fifth Domestic Unsecured Convertible Bonds

On September 8, 2020, the Company issued 15,000 units of New Taiwan Dollar-denominated zero-coupon unsecured convertible bonds totaling NT\$1,500,000 thousand.

In compliance with Article 7 of the Conversion Bond Act, effective from the issuance date of the sixth domestically secured convertible bond issuance (i.e., April 6, 2023), the Company set up an equivalent class of bonds or collateral rights in the same order as the secured convertible bond.

Holders of each unit of the convertible bonds are entitled to convert them into ordinary shares of the Company at NT\$90 per share. The conversion period for the convertible bonds is three months from the date when the convertible bonds were issued to the maturity date. Holders of the convertible bonds may request the Company to redeem the convertible bonds they held in cash at the par value of the convertible bonds plus an interest compensation equivalent to 102.27% (or an effective yield of 0.75%) of the par value of the convertible bonds at the end of three years from the issuance of the convertible bonds.

The convertible bonds consist of both debt and equity components, with the equity component being represented as capital surplus - stock options under equity items. The original recognized effective interest rate for the debt component is 3.0877%.

The amount of unconverted bonds due for repayment on September 8, 2025 was \$1,490,100 thousand. At the same time, \$167,864 thousand worth of convertibles whose conversion option has lapsed will be transferred from capital surplus - stock options to capital surplus - others.

During the issuance of the convertible bonds, the conversion option of the bonds was separated from liabilities. Information on the recognition of the convertible bonds in equity and liabilities is provided as follows:

The present value of the compound interest on convertible corporate bonds	\$ 1,288,418
Embedded derivative instrument - the right of redemption and put-back	38,760
Equity component at issuance	<u>168,979</u>
Issue price of convertible bonds (net of issuance costs of NT\$3,843 thousand)	\$ 1,496,157

C. Sixth Domestic Secured Convertible Bonds

On April 26, 2023, the Company issued 7,000 units of secured convertible bonds with a coupon rate of 0% and a total principal amount of NT\$700,000 thousand in Taiwan. The bonds were publicly underwritten by auction at 110.08% of face value, and the actual amount of bonds issued was NT\$770,583 thousand.

Each unit bondholder has the option to convert their bonds into ordinary shares of the company at a rate of NT\$48 per share. The conversion period for the convertible bonds is three months from the date when the convertible bonds were issued to the maturity date.

The convertible bonds consist of both debt and equity components, with the equity component being represented as capital surplus - stock options under equity items. The original recognized effective interest rate for the debt component is 2.647%.

During the issuance of the convertible bonds, the conversion option of the bonds was separated from liabilities. Information on the recognition of the convertible bonds in equity and liabilities is provided as follows:

The present value of the compound interest on convertible corporate bonds	\$	614,362
Embedded derivative instrument - the right of put-back		(5,488)
Equity component at issuance		160,623
Issue price of convertible bonds (net of issuance costs of NT\$1,086 thousand)	\$	769,497

D. Seventh Domestic Unsecured Convertible Bonds

On April 27, 2023, the Company issued 25,000 units of unsecured convertible bonds denominated in New Taiwan dollars with a coupon rate of 0% and a total principal amount of NT\$2,500,000 thousand in Taiwan.

Holders of each unit of the convertible bonds are entitled to convert them into ordinary shares of the Company at NT\$49 per share. The conversion period for the convertible bonds is three months from the date when the convertible bonds were issued to the maturity date. Holders of the convertible bonds may request the Company to redeem the convertible bonds they held in cash at the par value of the convertible bonds plus an interest compensation equivalent to 103.03% (or an effective yield of 1%) of the par value of the convertible bonds at the end of three years from the issuance of the convertible bonds.

The convertible bonds consist of both debt and equity components, with the equity component being represented as capital surplus - stock options under equity items. The original recognized effective interest rate for the debt component is 5.03917%.

During the issuance of the convertible bonds, the conversion option of the bonds was separated from liabilities. Information on the recognition of the convertible bonds in equity and liabilities is provided as follows:

The present value of the compound interest on convertible corporate bonds	\$	1,955,165
Embedded derivative instrument - the right of redemption and put-back		41,075
Equity component at issuance		499,918
Issue price of convertible bonds (net of issuance costs of NT\$3,842 thousand)	\$	2,496,158

(14) Employee benefits

A. Defined contribution plan

Since subsidiaries of the Company, including Center Biotherapeutics Inc., Centerlab Investment Holding Limited, Center Laboratories Limited, Center Venture Holding I Limited, Center Venture Holding II Limited, Center Venture Holding III Limited, Bioflag International Corporation, Bioflag Co., Ltd., and Genlac Biotech Inc. do not hire full-time employees, their investing activities are carried out by the Company and management consulting firms. Hence, there is no relevant pension system in these subsidiaries.

The pension system of the Labor Pensions Ordinance applies to the Company and Glac Biotech Co., Ltd. is a definitive allocation scheme, which has been allocated to the individual pension account of the Labor Insurance Bureau based on 6 percent of the employee's monthly salary since July 1, 2005.

The retirement pensions of the remaining subsidiaries are determined by the definite allocation system, and various social security funds such as pensions and medical care are paid to the local government every month according to laws and regulations.

The total recognized expenses for defined contribution plan in the income statement for the periods from July 1 to September 30, 2025 and 2024 and from January 1 to September 30, 2025 and 2024 were NT\$4,656 thousand, NT\$4,517 thousand, NT\$13,743 thousand and NT\$13,862 thousand, respectively.

B. Defined benefits plan

Where the Company and Glac Biotech Co., Ltd. adopt the government-managed defined benefit plan as their pension system applicable under the Labor Standards Act, each employee whose has served the company for up to 15 years, shall be given two bases for each full year of service rendered, while each employee who has served the Company over 15 years shall be given one base for each full year of service rendered. An employee shall not receive more than 45 bases in total. Employees' pension payments are based on the number of years of service and the average salary of the six months before the approved retirement date (the "basis"). The Company contributes 2% of salaries and wages to a monthly pension fund, which is deposited in the Bank of Taiwan in the name of the Labor Pension Fund Supervisory Committee.

Before the end of each year, if the balance in the account is inadequate to pay pensions to workers retiring in the same year, the difference has to be made up in a one-off contribution before the end of March the following year. This special account is managed by the Labor Fund Utilization Bureau of the Ministry of Labor, and the Company has no right to influence the investment management strategy.

According to the aforementioned regulations, the retirement benefit cost (profit) recognized as expenses in the income statement for the Company for the periods from July 1 to September 30, 2025 and 2024 and from January 1 to September 30, 2025 and 2024 were NT\$36 thousand, NT\$3 thousand, NT\$107 thousand and NT\$12 thousand, respectively.

(15) Equity

A. Ordinary shares

As of September 30, 2025, and 2024, the issued capital was NT\$10,000,000 thousand and the par value of each share is NT\$10, all of which are 1,000,000 thousand shares. As of September 30, 2025 and 2024, the paid-in capital amounted to NT\$7,249,768 thousand, consisting of 724,977 thousand shares of common stock.

Based on the resolution passed by the shareholders' meeting in June 2015, the Company conducted a private placement of ordinary shares by issuing 15,000 thousand ordinary shares at a premium of \$62.1 per share in November 2015, and raised \$931,500 thousand in capital, where the record date for capital increase was November 26, 2015. In June 2016, the Company issued 5,000 thousand ordinary shares at a premium of \$62.1 per share and raised \$310,500 thousand in capital, with the record date for the capital increase being June 22, 2016. The rights and obligations of the privately-placed ordinary shares are the same as those of other ordinary shares, except for the restrictions on transferability under the Securities and Exchange Act and the requirement that the shares must be held for three years from the date of delivery and must be reissued after the issuance of the shares to apply for over-the-counter quotations.

B. Capital surplus

Items	September 30, 2025	December 31, 2024	September 30, 2024
Issued at premium	\$ 3,510,412	\$ 4,054,144	\$ 4,054,144
Changes in net equity of associates and joint ventures accounted for using the equity method	709,310	665,876	1,080,768
Difference between consideration and carrying amount of subsidiaries acquired or disposed	21	—	—
Stock options	540,931	725,873	725,070
Treasury shares	88,455	88,455	88,455
Others	191,948	1,609	1,609
Total	<u>\$ 5,041,077</u>	<u>\$ 5,535,957</u>	<u>\$ 5,950,046</u>

(a) Increase in ordinary share premium is due to capital increase and convertible bond premium.

- (b) Changes in the net equity of associates and joint ventures accounted for using the equity method are due to difference in net equity arising from changes in the shareholders' equity of investees and changes in the percentage of ownership.
- (c) The difference between the acquisition or disposal of the equity price of a subsidiary company and the book value is the acquisition or sale of the equity of the subsidiary. Since it has not lost control, it is regarded as an equity transaction and transferred to the capital surplus.
- (d) According to the Company Act, capital surplus may not be used for any purpose other than to offset a deficit. However, capital surplus from the issue of stock in excess of par value (including the excess of par value of ordinary shares issued, capital surplus from stock issued in connection with a merger, and treasury stock transactions) and the proceeds from the receipt of gifts may be transferred to capital, and such transfer is limited to a certain percentage of the paid-in capital each year. Capital surplus from long-term investments may not be used for any purpose.

In addition, under the Company Law amended in January 2012, if a company has no losses, the capital surplus from the issue of stock in excess of par value and the capital surplus from gifts may be distributed in cash in proportion to the shareholders' original shareholdings.

C. Retained earnings

Based on the Articles of Association, the annual earnings of the Company shall be first appropriated to pay taxes and offset accumulated losses before allocating 10% of the remaining earning to the legal reserve (not applicable where accumulated legal reserve has reached the amount required by law and regulations) and a special reserve in accordance to the Company's operating needs and pursuant to the applicable law and regulations. Any retained earnings available for distribution together with accumulated undistributed retained earnings may be proposed by the Board of Directors to appropriate and be resolved at the Annual General Meeting.

According to the Company's Articles of Incorporation, a dividend policy aims to establish a comprehensive financial structure and ensure investors' interests; hence, the Company adopts a dividend equalization policy, where earnings to be appropriated shall be no less than 50% of the unappropriated earnings for the current year, and at least 10% of dividends to be distributed in the current year shall be distributed as cash dividends. If the distributed stock dividend for the current year is less than NT\$3, the earnings may all be distributed as stock dividends.

(a) Legal reserve

The legal reserve should be allocated until it reaches the total amount of the Company's paid-in capital. It can also be used to offset losses. According to the amended provisions of the Company Law announced on January 4, 2012, any excess amount of the legal reserve exceeding 25% of the total paid-in capital can be allocated to increase the capital or distributed in cash.

(b) Special reserve

The Company appropriates or reserves special reserve according to the Company's needs, which is subject to the resolution of the shareholders meeting, and in accordance with the Letter No. 1010012865, Letter No. 1010047490 and Letter No. 1030006415 issued by the FSC and the directive titled "Questions and Answers for Special Reserves Appropriated Following Adoption of IFRSs."

D. Appropriation of earnings

The Company resolved at the shareholders' meeting on June 26, 2025, to approve the distribution of earnings and the allocation of cash from the capital reserve as follows.

	2024	
	Amount	Dividends per share (NT\$)
Stock dividends	362,488	0.5
Cash dividends from capital surplus	543,732	0.75

The cash dividends from capital surplus, which were proposed and approved in the shareholders' meetings on June 25, 2024 was as follows:

	2023	
	Amount	Dividends per share (NT\$)
Cash dividends from capital surplus	1,037,159	1.50

For the appropriation of earnings proposed by the Board of Directors and approved by the shareholders' meeting at the Company, please visit the Market Observation Post System.

E. Other equity

Changes in other equity items for the nine months ended September 30, 2025 and 2024 are as follows:

	Unrealized gain (loss) on financial assets at fair value through other comprehensive income	Exchange differences arising on translation of foreign operations	Total
Balance as of January 1, 2025	\$ 19,603	\$ (739)	\$ 18,864
Exchange differences arising on translation of foreign operations	—	(58,910)	(58,910)
Share of other comprehensive income of associates and joint ventures accounted for using the equity method	—	(8,902)	(8,902)
Balance as of September 30, 2025	\$ 19,603	\$ (68,551)	\$ (48,948)

	Unrealized gain (loss) on financial assets at fair value through other comprehensive income	Exchange differences arising on translation of foreign operations	Total
Balance as of January 1, 2024	\$ 74,820	\$ (50,396)	\$ 24,424
Exchange differences arising on translation of foreign operations	—	43,294	43,294
Share of other comprehensive income of associates and joint ventures accounted for using the equity method	—	6,894	6,894
Balance as of September 30, 2024	\$ 74,820	\$ (208)	\$ 74,612

F. Treasury shares

(a) Reasons and quantities of treasury stock for the third quarter of 2025 and 2024:

Reason for Reacquisition	Third Quarter of 2025			Unit: thousand shares Number of Shares, End of Period
	Number of Shares, Beginning of Period	Increase in current period	Decrease in current period	
Shares of the Company held by subsidiaries	4,553	—	—	4,553
Transfer of Shares to Employees	—	9,909	—	9,909
Total	4,553	9,909	—	14,462

Reason for Reacquisition	Third Quarter of 2024			Unit: thousand shares Number of Shares, End of Period
	Number of Shares, Beginning of Period	Increase in current period	Decrease in current period	
Shares of the Company held by subsidiaries	5,358	—	805	4,553

As of September 30, 2025 and 2024, the market value of the treasury shares held by the subsidiaries of the Company was NT\$176,872 thousand and NT\$218,756 thousand, respectively.

- (b) According to the Securities and Exchange Act, the number of shares outstanding repurchased by the Company shall not exceed 10% of the number of issued shares, and the total amount repurchased shall not exceed the sum of the Company's retained earnings, share premium, and realized capital surplus.
- (c) According to the Securities and Exchange Act, treasury shares held by the Company shall not be pledged, and may not hold any shareholder rights before their transfer. The subsidiaries holding the aforementioned treasury shares are bestowed shareholders' rights, except the rights to participate in any capital increase by cash and to vote.

G. Non-controlling interests

Items	September 30, 2025	September 30, 2024
Beginning balance	\$ 6	\$ 459,349
Net income	—	275
Increase (decrease) in non-controlling interests in subsidiary acquisitions	—	(459,618)
Ending balance	<u>\$ 6</u>	<u>\$ 6</u>

(16) Share-based payment arrangements

A. As of September 30, 2025, the Company's equity-based compensation agreement is as follows:

Type of Agreement	Grant Date	Number of Shares Granted (thousand shares)	Contractual Period	Vesting Conditions
Employee Stock Option Plan	2024.11.21	3,000	4 years	Note 1

Note1: After an employee has been granted stock options and two years have elapsed, they may exercise their stock options according to the schedule and proportion specified in the plan, provided they are still employed and have achieved the operational performance targets.

B. Information on these employee stock warrants is provided as follows:

		Nine Months Ended September 30, 2025	
Employee Stock Warrants		Number of Units	Weighted Average Exercise Price (NT\$)
Stock warrants outstanding		3,000	\$ 50.50
Beginning Balance			
Forfeitures waived during the current period	(81)		50.50
Stock warrants outstanding at the end of the period	2,919		50.50
Stock warrants exercisable at the end of the period	—		
The weighted average of stock warrants granted	—		

C. As of September 30, 2025, the following information pertains to the employee stock options currently in circulation:

Range of Exercise Prices (NT\$)	Current External Units	Weighted Average Expected Remaining Duration (Years)	Weighted Average Exercise Price (NT\$)	Implementing Unit	Weighted Average Exercise Price of Exercisable Stock Warrants
50.5	2,919	3.14	50.5	—	—

D. The employee stock option above uses Black-Scholes option evaluation mode to estimate the fair value of the subscription option, and the information relating thereto is as follows:

Type of Agreement	Grant Date	Share Price	Exercise Price	Expected Volatility	Expected Lifetime	Expected Dividends	Risk-free Rate	Weighted Average Fair Value per Share (NT\$)
Employee Stock Option Plan	2024.11.21	50.5	50.5	29.51%	4 years	0.00%	1.41%~1.44%	10.01

E. The Company recognizes the compensation cost of NT\$5,350 thousand for the stock-based payment in the third quarter of 2025.

(17) Transactions with Non-controlling Interests

The Company formerly held 47.33% of the shares of Bioflag International Corporation through its subsidiary, Centerlab Investment Holding Limited. In May 2024, the Company acquired 52.67% of the shares of Bioflag International Corporation through the issuance of new shares. After the share exchange, Bioflag International Corporation became a wholly-owned subsidiary of the Company.

Items	September 30, 2024
Acquired book value of non-controlling interests	\$ 459,618
Payment of share consideration for non-controlling interests	(1,171,346)
Difference between acquisition price and carrying value of equity in subsidiaries	\$ (711,728)
Equity transaction balance adjustment account	
Capital surplus	\$ (449,327)
Accumulated Profit/Loss	\$ (262,401)

(18) Revenue from contracts with customers

A. Details of revenue

	Three Months Ended September 30, 2025		
	Pharmaceutical Division	Glac Segment	Total
Major Regional Markets			
Taiwan	239,425	54,321	293,746
China	—	57,723	57,723
Others	—	7,638	7,638
	239,425	119,682	359,107

	Nine Months Ended September 30, 2025		
	Pharmaceutical Division	Glac Segment	Total
Major Regional Markets			
Taiwan	714,914	168,685	883,599
China	—	212,727	212,727
Others	—	20,351	20,351
	714,914	401,763	1,116,677

	Nine Months Ended September 30, 2025		
	Pharmaceutical Division	Glac Segment	Total
Major Products/Services			
Western pharmaceuticals	714,914	—	714,914
Probiotics	—	401,763	401,763
Total	714,914	401,763	1,116,677

	Three Months Ended September 30, 2024		
	Pharmaceutical Division	Glac Segment	Total
Major Regional Markets			
Taiwan	225,684	55,568	281,252
China	—	96,848	96,848
Others	—	14,386	14,386
	225,684	166,802	392,486

	Three Months Ended September 30, 2024		
	Pharmaceutical Division	Glac Segment	Total
Major Products/Services			
Western pharmaceuticals	225,684	—	225,684
Probiotics	—	166,802	166,802
Total	225,684	166,802	392,486

	Nine Months Ended September 30, 2024		
	Pharmaceutical Division	Glac Segment	Total
<u>Major Regional Markets</u>			
Taiwan	713,969	155,484	869,453
China	—	268,635	268,635
Others	—	31,227	31,227
	<u>713,969</u>	<u>455,346</u>	<u>1,169,315</u>
<u>Major Products/Services</u>			
Western pharmaceuticals	713,969	—	713,969
Probiotics	—	455,346	455,346
Total	<u>713,969</u>	<u>455,346</u>	<u>1,169,315</u>

B. Contract assets and liabilities

Below are the contractual assets and contractual liabilities related to the customer contract revenues confirmed by the Company:

	September 30, 2025	December 31, 2024	September 30, 2024
Accounts receivable (including related parties)	\$ 168,841	\$ 180,354	\$ 174,410
Less: Loss allowance	(1,863)	(1,775)	(1,668)
	<u>\$ 166,978</u>	<u>\$ 178,579</u>	<u>\$ 172,742</u>
Contract liabilities - current			
Product Sales	\$ 145,626	\$ 157,323	\$ 177,022
Provision of Services	8,521	1,923	—
	<u>\$ 154,147</u>	<u>\$ 159,246</u>	<u>\$ 177,022</u>
Contract liabilities - non-current			
Provision of Services	\$ —	\$ 4,841	\$ —

Contract liabilities are mainly due to advance receipts from commodity sales contracts, which will be transferred to revenue when the products are delivered to customers.

(19) Employee benefits, depreciation, and amortization expenses are summarized by function as follows:

Function Nature	Three Months Ended September 30					
	2025		2024			
	Operating Costs	Operating Expenses	Total	Operating Costs	Operating Expenses	Total
Employee benefits expense						
Salaries	47,878	58,837	106,715	32,416	49,772	82,188
Labor and health insurance	4,611	4,731	9,342	4,281	4,321	8,602
Pension	2,145	2,476	4,621	2,061	2,453	4,514
Others	2,959	1,944	4,903	4,028	1,593	5,621
Subtotal	57,593	67,988	125,581	42,786	58,139	100,925
Depreciation	26,176	5,579	31,755	21,285	6,420	27,705
Amortization	73	12,556	12,629	13	12,734	12,747

Nature Function	Nine Months Ended September 30					
	2025			2024		
	Operating Costs	Operating Expenses	Total	Operating Costs	Operating Expenses	Total
Employee benefits expense						
Salaries	130,549	179,547	310,096	103,679	163,735	267,414
Labor and health insurance	13,466	14,238	27,704	12,282	13,565	25,847
Pension	6,276	7,360	13,636	6,020	7,830	13,850
Others	9,155	5,561	14,716	11,684	4,819	16,503
Subtotal	159,446	206,706	366,152	133,665	189,949	323,614
Depreciation	74,429	16,169	90,598	62,207	19,274	81,481
Amortization	146	37,656	37,802	38	37,113	37,151

The Company allocates 0.1% to 10% and no more than 2% of its net profit before tax before deducting employee compensation and remuneration of directors and supervisors for the current year, as compensation and remuneration of directors and supervisors, respectively in accordance with its Articles of Incorporation.

The Company's employee compensation and director and supervisor remuneration for the nine months ended September 30, 2025 are as follows:

	Third Quarter of 2025	
	Percentage	Amount
Employee compensation	0.2%	6,042
Remuneration to directors	0.2%	6,042

As a result of the pre-tax loss for the nine months ended September 30, 2024, the Company was unable to provide employee compensation.

Changes in accounting estimates subsequent to the adoption of the annual financial statements are recognized as adjustments in the following year.

For information on the distribution of employee compensation and remuneration of directors and supervisors approved by the Company's Board of Directors, please visit the Market Observation Post System.

(20) Non-operating income and expenses

A. Finance costs

Items	Three Months Ended September 30		Nine Months Ended September 30	
	2025	2024	2025	2024
Interest on bank loans	\$ 10,185	\$ 13,272	\$ 33,606	\$ 35,589
Interest on corporate bonds	34,119	37,146	107,636	115,333
Interest on lease liabilities	43	71	150	241
Others	(17)	11	—	27
Subtotal	44,330	50,500	141,392	151,190
Bank loan processing fee	2,201	9,684	19,754	23,309
Total	\$ 46,531	\$ 60,184	\$ 161,146	\$ 174,499

(21) Components of other comprehensive income

Three Months Ended September 30, 2025	Amount	Reclassification Adjustment	Other Comprehensive Income	Income Tax Benefit (Expense)	Amount After Tax
Items that may be reclassified subsequently to profit or loss:					
Exchange differences arising on translation of foreign operations	\$ 55,357	\$ —	\$ 55,357	\$ (11,072)	\$ 44,285
Share of other comprehensive income or loss of associates and joint ventures accounted for using the equity method	5,013	—	5,013	(332)	4,681
Other comprehensive income	<u>\$ 60,370</u>	<u>\$ —</u>	<u>\$ 60,370</u>	<u>\$ (11,404)</u>	<u>\$ 48,966</u>
Three Months Ended September 30, 2024	Amount	Reclassification Adjustment	Other Comprehensive Income	Income Tax Benefit (Expense)	Amount After Tax
Items that may be reclassified subsequently to profit or loss:					
Exchange differences arising on translation of foreign operations	\$ 8,826	\$ —	\$ 8,826	\$ (1,792)	\$ 7,034
Share of other comprehensive income or loss of associates and joint ventures accounted for using the equity method	(3,077)	—	(3,077)	339	(2,738)
Other comprehensive income	<u>\$ 5,749</u>	<u>\$ —</u>	<u>\$ 5,749</u>	<u>\$ (1,453)</u>	<u>\$ 4,296</u>
Nine Months Ended September 30, 2025	Amount	Reclassification Adjustment	Other Comprehensive Income	Income Tax Benefit (Expense)	Amount After Tax
Items that may be reclassified subsequently to profit or loss:					
Exchange differences arising on translation of foreign operations	\$ (73,637)	\$ —	\$ (73,637)	\$ 14,727	\$ (58,910)
Share of other comprehensive income or loss of associates and joint ventures accounted for using the equity method	(9,458)	—	(9,458)	556	(8,902)
Other comprehensive income	<u>\$ (83,095)</u>	<u>\$ —</u>	<u>\$ (83,095)</u>	<u>\$ 15,283</u>	<u>\$ (67,812)</u>

Nine Months Ended September 30, 2024	Amount	Reclassification Adjustment	Other Comprehensive Income	Income Tax Benefit (Expense)	Amount After Tax
Items that may be reclassified subsequently to profit or loss:					
Exchange differences arising on translation of foreign operations	\$ 57,632	\$ (3,454)	\$ 54,178	\$ (10,884)	\$ 43,294
Share of other comprehensive income or loss of associates and joint ventures accounted for using the equity method	7,740	(887)	6,853	41	6,894
Other comprehensive income	<u>\$ 65,372</u>	<u>\$ (4,341)</u>	<u>\$ 61,031</u>	<u>\$ (10,843)</u>	<u>\$ 50,188</u>

(22) Income tax

A. Deferred tax assets (liabilities)

Items	September 30, 2025	December 31, 2024	September 30, 2024
Deferred tax assets			
Less: Allowance for inventory valuation losses	\$ 3,967	\$ 3,967	\$ 2,354
Unrealized gain on financial assets	(5,011)	20,733	6,849
Investments accounted for using the equity method	9,694	9,481	9,499
Exchange differences arising on translation of foreign operations	(1,342)	(1,817)	(1,785)
Others	<u>141</u>	<u>141</u>	<u>1,380</u>
Subtotal	<u><u>\$ 7,449</u></u>	<u><u>\$ 32,505</u></u>	<u><u>\$ 18,297</u></u>
Deferred tax liabilities			
Less: Allowance for inventory valuation losses	\$ 1,382	\$ 1,299	\$ 974
Bonds payable	(43,708)	(66,818)	(76,942)
Unrealized gain on financial assets	30,625	60,093	(16,298)
Land value increment tax	(11,718)	(11,718)	(11,718)
Investments accounted for using the equity method	(613,177)	(122,048)	(181,063)
Others	<u>(726)</u>	<u>(6,041)</u>	<u>3,278</u>
Exchange differences arising on translation of foreign operations	11,301	(3,508)	(2,719)
Subtotal	<u><u>\$ (626,021)</u></u>	<u><u>\$ (148,741)</u></u>	<u><u>\$ (284,488)</u></u>

B. Details of the Company's income tax expense recognized in gain or loss are provided as follows:

Items	Three Months Ended September 30		Nine Months Ended September 30	
	2025	2024	2025	2024
Current income tax expense	\$ 9,200	\$ 29,853	\$ 26,784	\$ 190,054
Deferred income tax expense (benefit)	561,300	110,790	519,333	(167,456)
Income basic tax	252	44	667	10,008
Repayment of income taxes in prior years	—	—	—	413
Underestimated (overestimated) income tax in prior years	(33,935)	—	(49,262)	(3,260)
Other (Withholding Tax)	—	(190)	—	15,649
Income tax expense (benefit)	\$ 536,817	\$ 140,497	\$ 497,522	\$ 45,408

C. Income tax recognized in other comprehensive income

Items	Three Months Ended September 30		Nine Months Ended September 30	
	2025	2024	2025	2024
Exchange differences arising on translation of foreign operations	\$ 11,072	\$ 1,792	\$ (14,727)	\$ 10,884
Share of other comprehensive income or loss of associates and joint ventures accounted for using the equity method	332	(339)	(556)	(41)
Income tax expense (benefit) relating to items that may be reclassified to profit or loss	\$ 11,404	\$ 1,453	\$ (15,283)	\$ 10,843

D. The Company's business income tax has been checked and approved by the taxation authority until 2023.

(23) Earnings per share

	Three Months Ended September 30					
	2025		2024			
	Net income	Weighted average shares	Earnings per share (NT\$)	Net income	Weighted average shares	Earnings per share (NT\$)
Basic earnings per share	2,717,594	715,068	3.80	273,310	722,752	0.38
Dilutive potential ordinary shares	—	—	—	—	—	(Note)
Employee compensation	—	—	—	—	—	(Note)
Convertible bonds	20,014	61,587	—	29,717	98,235	—
Diluted earnings per share	2,737,608	776,655	3.52	303,027	820,987	0.37

	Nine Months Ended September 30					
	2025			2024		
	Net income	Weighted average shares	Earnings per share (NT\$)	Net income	Weighted average shares	Earnings per share (NT\$)
Basic earnings per share	2,540,198	720,804	3.52	(340,136)	704,716	(0.48)
Dilutive potential ordinary shares						
Employee compensation	—	—	—	—	(Note)	
Convertible bonds	58,911	61,587	—	—	(Note)	
Diluted earnings per share	2,599,109	782,392	3.32	(340,136)	704,716	(0.48)

(Note) In calculating the surplus per diluted share, the inclusion of potential ordinary shares in the calculation of net gain (loss) per share will have a dilution effect and are not included in the calculation.

On June 26, 2025, the Company resolved at the shareholders' meeting to issue stock dividends without charge. If this stock dividend issuance occurs before the financial statements are approved for release, the retroactive adjustments to earnings per share are as follows:

	Three Months Ended September 30		Nine Months Ended September 30	
	2025		2024	
	Basic earnings per share (NT\$)	Diluted earnings per share (NT\$)	Basic earnings per share (NT\$)	Diluted earnings per share (NT\$)
Basic earnings per share (NT\$)	\$ 3.62	\$ 3.35	\$ 0.36	\$ 3.52
Diluted earnings per share (NT\$)	\$ 3.62	\$ 3.35	\$ 0.36	\$ 3.52

When the Company decides to distribute employee compensation in the form of stocks or cash, diluted earnings per share should be calculated based on the assumption that the employee compensation will be distributed in the form of stocks. The weighted average number of outstanding shares should include the potential ordinary shares that have a dilutive effect in order to calculate diluted earnings per share. Additionally, when calculating diluted earnings per share prior to the distribution of employee dividends at the next annual shareholders' meeting, the dilutive effect of these potential ordinary shares should also be considered.

(24) Cash flow information

A. Investment activities involving only partial cash payments:

(a)

	Nine Months Ended September 30	
	2025	2024
Increase in property, plant and equipment	\$ 119,600	\$ 98,648
Increase in prepayment for equipment	16,822	16,054
Changes in payables for construction and equipment	4,003	5,624
Payments for acquisition of property, plant and equipment (Including prepayment for equipment)	\$ 140,425	\$ 120,326

(b)

	Nine Months Ended September 30	
	2025	2024
Cash dividends distributed by parent company	\$ 543,732	\$ 1,037,159
Less: Dividends payable	(543,732)	—
Dividends distributed by subsidiaries	—	(6,513)
Cash payment for dividends distributed	\$ —	\$ 1,030,646

B. Significant Non-Cash Transactions

The Group's investments and financing activities in non-cash transactions from January 1 to September 30, 2024 were as follows:

(a) On May 31, 2024, the Company acquired the remaining 52.67% equity of Bioflag International Corporation by issuing ordinary shares with a fair value totaling \$1,171,346 thousand (see Note 6 (17)).

C. Changes in Debt from Fundraising Activities

	Nine Months Ended September 30, 2025			
	Short-term loans	Long-term loans	Bonds payable	Lease payables
January 1	1,262,000	1,061,121	4,189,621	17,387
Cash flows from financing activities	(282,000)	91,699	(1,988,700)	(7,129)
New Lease	—	—	—	709
Other non-cash changes	—	—	107,636	—
September 30	<u>980,000</u>	<u>1,152,820</u>	<u>2,308,557</u>	<u>10,967</u>
	Nine Months Ended September 30, 2024			
	Short-term loans	Long-term loans	Bonds payable	Lease payables
January 1	330,000	913,982	4,350,826	26,569
Cash flows from financing activities	962,000	(650,124)	—	(6,872)
New Lease	—	—	—	—
Other non-cash changes	—	—	(197,644)	—
September 30	<u>1,292,000</u>	<u>263,858</u>	<u>4,153,182</u>	<u>19,697</u>

(25) Capital management

Based on the characteristics of the industries in which the Company is currently operating and the future development of the Company, as well as taking into account factors such as changes in the external environment, the Company plans its needs for working capital, research and development expenses, and dividend payments in future periods, with a view to safeguarding the Company's ability to continue as a going concern, giving back to its shareholders while attending to the interests of other stakeholders, and maintaining an optimal capital structure to enhance shareholder value over the long run.

In order to maintain or adjust its capital structure, the Company may adjust the amount of dividends paid to shareholders by issuing new shares, distributing cash to shareholders or repurchasing its shares.

The Company regularly reviews the asset-liability ratio to monitor its funds. The capital of the Company is represented by "total equity" listed in the balance sheet, which is calculated as the total assets minus total liabilities.

The Company's debt ratios are listed as follows:

Items	September 30, 2025	December 31, 2024	September 30, 2024
Total liabilities	\$ 6,171,996	\$ 7,482,692	\$ 6,743,158
Total assets	\$ 25,809,420	\$ 25,537,175	\$ 26,027,630
Debt ratio	24%	29%	26%

(26) Financial instruments

A. Information on Fair Value of Financial Instruments

Except as detailed in the table below, the carrying amounts of the Group's financial instruments not measured at fair value (including cash and cash equivalents, time deposits, notes receivable, accounts receivable, other receivables, long-term and short-term loans, refundable deposits, bills payable, accounts payable and other payables) approximate their fair values. For information on the fair value of financial instruments that are measured at fair value, please refer to Note 6.(26(C)).

	September 30, 2025			
	Carrying Amount	Fair Value		
		Level 1	Level 2	Level 3
Financial liabilities				
Convertible bonds	2,308,557	—	—	2,299,682
	December 31, 2024			
	Carrying Amount	Fair Value		
		Level 1	Level 2	Level 3
Financial liabilities				
Convertible bonds	4,189,621	—	—	4,141,273
	September 30, 2024			
	Carrying Amount	Fair Value		
		Level 1	Level 2	Level 3
Financial liabilities				
Convertible bonds	4,153,182	—	—	4,109,166

B. Fair Value Hierarchy

The following table provides a related analysis of financial instruments that are measured at fair value after initial recognition and are categorized into Levels 1 through 3 based on the degree to which the fair value is observable. Each fair value level is defined as follows.

- (a) Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities.
- (b) Level 2: Other than quoted prices included within Level 1, inputs are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

(c) Level 3: Derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).

C. Financial instruments measured at fair value are classified according to the nature, characteristics and risks of assets and liabilities and the level of the fair value hierarchy as follows:

	September 30, 2025			
	Level 1	Level 2	Level 3	Total
Financial assets at fair value through profit or loss - current:				
Foreign listed stocks	\$ 497,211	\$ —	\$ —	\$ 497,211
Financial assets at fair value through profit or loss - non-current:				
Foreign funds	\$ —	\$ —	\$ 4,577,893	\$ 4,577,893
Domestic unlisted stocks and emerging stocks	—	191,514	16,543	208,057
Foreign unlisted stocks and equity	—	—	4,119,340	4,119,340
Domestic listed stocks	2,459,193	—	—	2,459,193
Foreign listed stocks	4,272,477	—	—	4,272,477
Hybrid financial assets	—	—	5,339	5,339
Redemption rights	—	—	1,470	1,470
Total	<u>\$ 6,731,670</u>	<u>\$ 191,514</u>	<u>\$ 8,720,585</u>	<u>\$ 15,643,769</u>
Financial liabilities at fair value through profit or loss - non-current:				
Put options	\$ —	\$ —	\$ 53,568	\$ 53,568

	December 31, 2024			
	Level 1	Level 2	Level 3	Total
Financial assets at fair value through profit or loss - current:				
Foreign listed stocks	\$ 257,998	\$ —	\$ —	\$ 257,998
Financial assets at fair value through profit or loss - non-current:				
Foreign funds	\$ —	\$ —	\$ 4,434,912	\$ 4,434,912
Domestic unlisted stocks and emerging stocks	—	174,156	18,511	192,667
Foreign unlisted stocks and equity	—	—	4,499,462	4,499,462
Domestic listed stocks	2,567,288	—	—	2,567,288
Foreign listed stocks	1,351,278	—	—	1,351,278
Redemption rights	—	—	3,117	3,117
Total	<u>\$ 3,918,566</u>	<u>\$ 174,156</u>	<u>\$ 8,956,002</u>	<u>\$ 13,048,724</u>
Financial liabilities at fair value through profit or loss - non-current:				
Put options	\$ —	\$ —	\$ 46,158	\$ 46,158

	September 30, 2024			
	Level 1	Level 2	Level 3	Total
Financial assets at fair value through profit or loss - current:				
Foreign listed stocks	\$ 320,402	\$ —	\$ —	\$ 320,402
Financial assets at fair value through profit or loss - non-current:				
Foreign funds	\$ —	\$ —	\$ 4,321,663	\$ 4,321,663
Domestic unlisted stocks and emerging stocks	—	169,555	11,516	181,071
Foreign unlisted stocks and equity	—	—	4,313,356	4,313,356
Domestic listed stocks	2,949,924	—	—	2,949,924
Foreign listed stocks	1,741,421	—	—	1,741,421
Redemption rights	—	—	3,467	3,467
Total	\$ 4,691,345	\$ 169,555	\$ 8,650,002	\$ 13,510,902
Financial liabilities at fair value through profit or loss – non-current:				
Put options	\$ —	\$ —	\$ 31,945	\$ 31,945

D. The methods and assumptions used by the Group to measure fair value are explained as follows:

(a) Where the Company adopts the market quotation as the fair value input (i.e., Level 1), it is listed as follows according to the characteristics of the instrument:

	Listed Stocks	Open-end Funds
Quoted market price	Closing price	Net worth

(b) Except for the above financial instruments with active markets, the fair values of other financial instruments are obtained by using valuation techniques or by reference to counterparty quotes. Fair values obtained using valuation techniques can be determined by reference to the current fair value of other instruments with substantially the same conditions and characteristics and discounted cash flow analysis or using other valuation techniques, including using models based on market information available at the consolidated balance sheet date (e.g., reference yield curve on Taipei Exchange and commercial paper rates on Reuters).

(c) The evaluation of derivative financial instruments is based on widely accepted valuation models in the market, such as the discounted cash flow method and option pricing models. Forward foreign exchange contracts are usually evaluated based on the current forward exchange rate. Structured interest rate derivative financial instruments are evaluated using

appropriate option pricing models, such as the Black-Scholes model, or other valuation methods, such as Monte Carlo simulation.

(d) Quantitative information on significant unobservable inputs used in valuation models for Level 3 fair value measurements and sensitivity analysis of changes in significant unobservable inputs are provided as follows:

	Fair Value as of September 30, 2025	Valuation technique	Significant Unobservable Inputs	Relationship between Inputs and Fair Value
Non-derivative instruments:				
Non-listed stocks	3,686,340	Comparable company approach	Price-to-earnings ratio, price-to- book ratio, enterprise value- to-operating income ratio, enterprise value- to-earnings before interest, taxes, depreciation, and amortization ratio, discount for lack of marketability, and control premium	The higher the ratios and control premium, the higher the fair value; The higher the discount for lack of marketability, the lower the fair value;
	—	Discounted cash flow approach	Long-term revenue growth rate, weighted average cost of capital, discount for lack of marketability, and discount for minority interest	The higher the weighted average cost of capital and discount for lack of marketability, the lower the fair value; The higher the long-term revenue growth rate and long-term net operating profit before tax, the higher the fair value.
Shares of venture capital company	449,543	Net asset value approach	Not applicable.	Not applicable.
Privately offered fund investments	4,577,893	Net asset value approach	Not applicable.	Not applicable.
Hybrid instrument: Put option	53,568	Monte Carlo simulation	Volatility and discount rate	The higher the volatility, the higher the fair value; the higher the discount rate, the lower the fair value
Hybrid instruments	6,809	Monte Carlo simulation	Volatility and discount rate	The higher the volatility, the higher the fair value; the higher the discount rate, the lower the fair value

	Fair value as of September 30, 2024	Valuation technique	Significant Unobservable Inputs	Relationship between Inputs and Fair Value
Non-derivative instruments:				
Non-listed stocks	3,867,069	Comparable company approach	Price-to-earnings ratio, price-to- book ratio, enterprise value- to-operating income ratio, enterprise value- to-earnings before interest, taxes, depreciation, and amortization ratio, discount for lack of marketability, and control premium	The higher the ratios and control premium, the higher the fair value; The higher the discount for lack of marketability, the lower the fair value;
	—	Discounted cash flow approach	Long-term revenue growth rate, weighted average cost of capital, discount for lack of marketability, and discount for minority interest	The higher the weighted average cost of capital and discount for lack of marketability, the lower the fair value; The higher the long-term revenue growth rate and long-term net operating profit before tax, the higher the fair value.
Shares of venture capital company	457,803	Net asset value approach	Not applicable.	Not applicable.
Privately offered fund investments	4,321,663	Net asset value approach	Not applicable.	Not applicable.
Hybrid instrument: Put option	31,945	Monte Carlo simulation	Volatility and discount rate	The higher the volatility, the higher the fair value; the higher the discount rate, the lower the fair value
Hybrid instrument: Right of redemption	3,467	Monte Carlo simulation	Volatility and discount rate	The higher the volatility, the higher the fair value; the higher the discount rate, the lower the fair value

E. Financial Risk Management Objectives

The Company's financial risk management objective is to manage market risk, credit risk, and liquidity risk associated with our operations. To mitigate these financial risks, we are dedicated to identifying, assessing, and mitigating market uncertainties in order to minimize the potential negative impact of market fluctuations on our financial performance.

The Board of Directors reviews the significant financial activities of in accordance with applicable regulations and internal control systems. The Company must adhere to the relevant financial operational procedures for overall financial risk management and division of responsibilities during the execution of financial plans.

F. Market Risk

Market risk refers to the potential impact of market price fluctuations, including exchange rates, interest rates, and equity security prices, on a company's earnings and the value of its financial instruments. The goal of market risk management is to maintain market risk at an acceptable level while maximizing investment returns.

(a) Exchange Rate Risk

Information on financial assets and liabilities denominated in foreign currencies that are material to the Group is listed as follows:

	September 30, 2025			December 31, 2024			September 30, 2024		
	Foreign currency	Exchange rate	NTD	Foreign currency	Exchange rate	NTD	Foreign currency	Exchange rate	NTD
(Foreign currency: Functional currency)									
<u>Financial assets</u>									
<u>Monetary items</u>									
USD: NTD	2,873	30.445	87,233	37,465	32.785	1,228,300	41,821	31.65	1,323,642
RMB: NTD	5,503	4.271	23,504	10,260	4.478	45,944	70,139	4.523	317,241
HKD: NTD	60	3.732	235	89	4.222	373	42	4.075	172
JPY: NTD	-	-	-	106,128	0.210	22,276	186,527	0.2223	41,465
<u>Non-monetary items</u>									
USD: NTD	159,167	30.445	4,845,833	150,938	32.785	4,948,505	158,436	31.65	5,014,484
RMB: NTD	1,101,382	4.271	4,704,002	1,072,623	4.478	4,803,206	1,045,307	4.523	4,727,926
KRW: NTD	646,258	0.0219	14,515	646,258	0.0225	14,515	927,553	0.0243	22,567
HKD: NTD	1,234,662	3.913	4,831,232	402,843	4.222	1,700,803	505,943	4.075	2,061,719
CHF: NTD	9,159	38.245	350,273	12,076	36.265	437,926	12,601	37.545	473,095

Due to a wide variety of foreign currencies involved in foreign currency transactions, exchange gains and losses are summarized and disclosed based on various foreign currencies of the consolidated company with material impact. All the exchange gains (losses) (including realized and unrealized) recognized for third quarter of 2025 and 2024 due to changes in exchange rates were NT\$(62,992) thousand and NT\$37,104 thousand, respectively.

(b) Interest Rate Risk

Interest rate risk refers to a type of risk in which the fair value of financial instruments changes due to market changes. The Company's interest rate risk mainly arises from floating-rate borrowings.

The carrying amounts of the Company's financial assets and liabilities that are exposed to interest rate risk at the balance sheet date are listed as follows:

Item	September 30, 2025	December 31, 2024	September 30, 2024
Exposed to cash flow interest rate risk			
— Financial liabilities	\$ 2,132,820	\$ 2,323,121	\$ 1,555,858

Sensitivity Analysis

The sensitivity analysis below is based on the interest rate risk of financial instruments as of the balance sheet date.

Floating-rate liabilities are analyzed based on the assumption that the amount of liabilities outstanding at the balance sheet date remains outstanding throughout the year.

Assuming all other variables remain constant, a one percentage point increase in the interest rate would lead to a decrease in the Company's pre-tax net profit for third quarter of 2025 and 2024 by NT\$15,996 thousand and NT\$11,669 thousand, respectively.

G. Credit Risk

The Company faces potential credit risks primarily from its cash and cash equivalents, as well as financial instruments receivable. The Company holds its cash in various financial institutions and manages its exposure to credit risks at each institution. It believes that its cash and cash equivalents do not have a significant concentration of credit risks. The Company's main business is the sale of Western pharmaceuticals, serving a wide customer base across diverse sales regions. There is no significant concentration of credit risks in accounts receivable from transactions with individual customers.

H. Liquidity Risk

The objective of the Company's management of liquidity risk is to maintain sufficient cash and cash equivalents, highly liquid marketable securities and adequate bank facilities required for its operations, so that the Company possesses ample financial flexibility.

The table below summarizes the maturity profile of the Company's financial liabilities based on contractual undiscounted payments.

Items	September 30, 2025			Total
	Less than 1 year	1 to 5 years	More than 5 years	
Short-term loans	\$ 980,000	\$ —	\$ —	\$ 980,000
Accounts payable	107,765	—	—	107,765
Other payables and others	757,821	—	—	757,821
Lease liabilities	9,514	1,844	—	11,358
Bonds payable	1,944,300	636,200	—	2,580,500
Long-term loans	36,785	1,116,035	—	1,152,820
Total	<u>\$ 3,836,185</u>	<u>\$ 1,754,079</u>	<u>\$ —</u>	<u>\$ 5,590,264</u>

December 31, 2024				
Items	Less than 1 year	1 to 5 years	More than 5 years	Total
Short-term loans	\$ 1,262,000	\$ —	\$ —	\$ 1,262,000
Accounts payable	134,790	—	—	134,790
Other payables and others	433,292	—	—	433,292
Lease liabilities	9,395	8,145	—	17,540
Bonds payable	1,988,700	2,580,500	—	4,569,200
Long-term loans	641,123	416,945	3,053	1,061,121
Total	<u>\$ 4,469,300</u>	<u>\$ 3,005,590</u>	<u>\$ 3,053</u>	<u>\$ 7,477,943</u>

September 30, 2024				
Items	Less than 1 year	1 to 5 years	More than 5 years	Total
Short-term loans	\$ 1,292,000	\$ —	\$ —	\$ 1,292,000
Accounts payable	113,908	—	—	113,908
Other payables and others	370,459	—	—	370,459
Lease liabilities	9,455	10,473	—	19,928
Bonds payable	1,988,700	2,580,500	—	4,569,200
Long-term loans	41,038	216,687	6,133	263,858
Total	<u>\$ 3,815,560</u>	<u>\$ 2,807,660</u>	<u>\$ 6,133</u>	<u>\$ 6,629,353</u>

7. RELATED PARTY TRANSACTIONS

(1) Name and Relationship of Related Parties

Name of Related Party	Relationship with the Group
Mycenax Biotech Inc.	Associate
BioEngine Technology Development Inc.	Subsidiary
Lumosa Therapeutics Co., Ltd.	Associate
BioGend Therapeutics Co., Ltd.	Associate
Anya Biopharm Inc.	Associate
TOT BIOPHARM Company Limited	Subsidiary of the Company's associate
Youluck International Inc.	Substantive
Ausnutria Dairy (Taiwan) Nutrition & Health Corporation	Substantive
Wechen Co., Ltd.	Directors of the Company
Youde Investment Consulting Co., Ltd.	The chairman of the Company is the person in charge of this Company.

(2) Significant transactions between the Company and related parties are listed as follows:

A. Other expenses

Type/Name of Related Party	Three Months Ended September 30		Nine Months Ended September 30	
	2025	2024	2025	2024
Associate	\$ 592	\$ 90	\$ 1,591	\$ 435
Other related party	—	—	—	24
Total	\$ 592	\$ 90	\$ 1,591	\$ 459

B. Lease income

Type/Name of Related Party	Three Months Ended September 30		Nine Months Ended September 30	
	2025	2024	2025	2024
Other related party	\$ 163	\$ 237	\$ 638	\$ 752
Associate	1,835	1,778	5,490	5,273
Lumosa Therapeutics Co., Ltd.	1,080	1,080	3,240	3,240
Total	\$ 3,078	\$ 3,095	\$ 9,368	\$ 9,265

C. Miscellaneous income

Type/Name of Related Party	Three Months Ended September 30		Nine Months Ended September 30	
	2025	2024	2025	2024
Associate	\$ 1,460	\$ 2,082	\$ 3,750	\$ 4,633
Other related party	101	102	304	1,257
Total	\$ 1,561	\$ 2,184	\$ 4,054	\$ 5,890

D. Accounts receivable (payable)

The debts and claims of the Company and its subsidiaries with related parties are listed as follows:

(a) Other receivables

Type/Name of Related Party	September 30, 2025		December 31, 2024	
	2025	2024	2025	2024
Associate	\$ 1,317	\$ 1,231	\$ 1,323	\$ 1,323
Other related party	192	275	278	278
Total	\$ 1,509	\$ 1,506	\$ 1,601	\$ 1,601

(b) Other payables

Type/Name of Related Party	September 30, 2025		December 31, 2024	
	2025	2024	2025	2024
Associate	\$ 211	\$ 32	\$ 31	\$ 31

(c) Other current liabilities

Type/Name of Related Party	September 30, 2025	December 31, 2024	September 30, 2024
Associate	\$ 995	\$ 958	\$ 981
Other related party	11	73	85
Total	<u>\$ 1,006</u>	<u>\$ 1,031</u>	<u>\$ 1,066</u>

(d) Guarantee deposits

Type/Name of Related Party	September 30, 2025	December 31, 2024	September 30, 2024
BioGend Therapeutics Co., Ltd.	\$ 565	\$ 565	\$ 565

E. Information on Compensation of Key Management Personnel

Items	Three Months Ended September 30		Nine Months Ended September 30	
	2025	2024	2025	2024
Salaries and other short-term employee benefits	\$ 9,420	\$ 2,570	\$ 16,758	\$ 9,608
Post-employment benefits	27	27	81	108
Share-based payments	207	—	607	—
Total	<u>\$ 9,654</u>	<u>\$ 2,597</u>	<u>\$ 17,446</u>	<u>\$ 9,716</u>

8. PLEDGED ASSETS

The following assets of the Company have been provided to financial institutions as collateral for borrowings or have been placed under restrictions as to use:

Name of Pledged Asset	September 30, 2025	December 31, 2024	September 30, 2024	Contents of the Guaranteed Debt
Property, plant and equipment	\$ 824,529	\$ 827,283	\$ 801,505	Bank loan and credit line guarantee
Investment property, net	659,221	662,247	663,261	Bank loan and credit line guarantee
Investments accounted for using the equity method	3,157,476	3,328,965	3,261,703	Guarantee for bank loan
Financial assets at fair value through profit or loss	75,810	75,600	89,040	Initial public offering lockup
Financial assets at fair value through profit or loss	3,877,011	1,565,165	1,475,970	Guarantee for bank loan
Other financial assets - Time deposits	—	924,974	920,430	Corporate bond guarantee and bank loan collateral
Other financial assets - Restricted demand deposits	294,340	258,509	238,138	Guarantee limits for repayment accounts and corporate bonds
Total	<u>\$ 8,888,387</u>	<u>\$ 7,642,743</u>	<u>\$ 7,450,047</u>	

9. SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNIZED CONTRACT COMMITMENTS

- (1) As of September 30, 2025 and 2024, the consolidated companies had outstanding contracts for commissioned drug trial development amounting to NT\$14,747 thousand and NT\$4,357 thousand, of which NT\$5,961 thousand and NT\$3,068 thousand, respectively, had been paid in accordance with the contracts.
- (2) As of September 30, 2025 and 2024, the consolidate company has entered into outstanding capital expenditures amounting to NT\$83,013 thousand and NT\$72,842 thousand, respectively for the construction of new plants and the acquisition of equipment.
- (3) In August 2010, the Company commissioned TTY Biopharm Company Limited to carry out formulation design and process development for R-PLGA long-acting freeze-dried powder injection dosage forms, with a commissioned development contract totaling \$20,000 thousand. As of June 30, 2025, the Company had paid \$12,500 thousand in accordance with the contract.
- (4) In October 2010, the Company entered into licensing contracts with the Industrial Technology Research Institute for the “D-PLGA Microparticle New Dosage Form Technology” and the “PLGA Microparticle Long-Acting Controlled-Release Platform Technology and Patent,” with a contract royalty of NT\$5,600 thousand payable and an annual royalty of 4% of the net sales of the products for 10 years from the date when sales of the products commences. As of September 30, 2025, the Company has paid a royalty of NT\$3,800 thousand.

10. SIGNIFICANT DISASTER LOSS: NONE

11. SIGNIFICANT SUBSEQUENT EVENTS: NONE

12. OTHERS: NONE

13. ADDITIONAL DISCLOSURES

- (1) Information on Significant Transactions and Investees

No.	Items	Description
1.	Parties providing financing to others	None
2.	Endorsement/guarantee provided	None
3.	Significant securities held at the end of the period (excluding investments in subsidiaries, affiliated enterprises, and jointly controlled entities).	Table 1
4.	Purchases from and sales to related parties amounting to at least NT\$100 million or 20% of the paid-in capital	None
5.	Receivables from related parties amounting to at least NT\$100 million or 20% of the paid-in capital	None

(2) Disclosure of Information on Investees

No.	Items	Description
1.	Information on investees (excluding information on investment in Mainland China)	Table 2
2.	Disclosure of control over investment companies	Table 1, 2

(3) Information on Investment in Mainland China:

No.	Items	Description
1.	The name of the mainland investee company, main business items, paid-in capital, investment method, capital access situation, shareholding ratio, investment gains, and losses, the book value of the investment at the end of the period, repatriated investment gains and losses, and investment limits in mainland China	Table 3
2.	Significant transactions with investees in Mainland China, either directly or indirectly through a third area, as well as prices, payment terms, and unrealized gains or losses involved therein	None

(4) Business relationships between the parent and subsidiaries and significant transactions between them: Table 4

14. SEGMENT INFORMATION

(1) Reportable Segment Information

The reportable segments provided to the main business decision-makers for the purposes of allocating resources and assessing segment performance are listed as follows:

Pharmaceutical division: Manufacturing and sales of various western pharmaceuticals.

Biotechnology venture capital- Investing in domestic and foreign biotechnology undertakings.

Glac segment - Manufacture and sale of probiotic products.

Other segments - Other businesses and operating segments that are not reported.

(2) The financial information of related reportable segments is analyzed as follows:

	Third Quarter of 2025					
	Pharmaceutical Division	Biotech Venture Capital	Glac Segment	Other Segments	Adjustments and Write-offs	Mergers
Income from customers other than the parent and subsidiaries	714,914	—	401,763	—	—	1,116,677
Income from the parent company and consolidated subsidiary	—	14,602	965	—	(15,567)	—
Total revenue	714,914	14,602	402,728	—	(15,567)	1,116,677
Segment profit (loss)	181,735	3,347,279	(38,881)	(513)		3,489,620
Investment income (loss)						(304,555)
Ordinary income (expenses)						13,801
Finance costs						(161,146)
Net income before tax of continuing operations						3,037,720
Identifiable assets	618,261	17,887,083	1,582,955	10,642		20,098,941
Long-term equity investments						5,312,120
Ordinary assets						398,359
Total assets	618,261	17,887,083	1,582,955	10,642		25,809,420

	Third Quarter of 2024					
	Pharmaceutical Division	Biotech Venture Capital	Glac Segment	Other Segments	Adjustments and Write-offs	Mergers
Income from customers other than the parent and subsidiaries	713,969	—	455,346	—	—	1,169,315
Income from the parent company and consolidated subsidiary	—	15,892	597	—	(16,489)	—
Total revenue	713,969	15,892	455,943	—	(16,489)	1,169,315
Segment profit (loss)	220,688	(86,214)	24,544	(384)		158,634
Investment income (loss)						(271,949)
Ordinary income (expenses)						(6,639)
Finance costs						(174,499)
Net income before tax of continuing operations						(294,453)
Identifiable assets	564,550	17,591,914	1,692,006	11,516		19,859,986
Long-term equity investments						5,769,286
Ordinary assets						398,358
Total assets	564,550	17,591,914	1,692,006	11,516		26,027,630

Table 1

Significant marketable securities held by the Company as of September 30, 2025 (excluding investments in subsidiaries, associates, and joint ventures):
In Thousands of New Taiwan Dollars

Name of Company Held	Type and Name of Securities	Relationship with Securities Issuer	Financial Statement Account	Ending Balance			
				Shares	Carrying Amount	Shareholding percentage	Fair Value
Center Laboratories, Inc.	Windtree Therapeutics, Inc. - Ordinary shares	—	Financial assets at fair value through profit or loss - current	27	—	11.10%	—
Center Laboratories, Inc.	Ausnutria Dairy Corporation Ltd.	—	Financial assets at fair value through profit or loss - current	29,282,627	303,645	1.64%	303,645
Center Laboratories, Inc.	Hydrogenic Energy Fund I L.P.	—	Financial assets at fair value through profit or loss - non-current	—	128,755	19.39%	128,755
Center Laboratories, Inc.	Vivo Capital Fund X, L.P.	—	Financial assets at fair value through profit or loss - non-current	—	166,351	2.08%	166,351
Center Laboratories, Inc.	Vivo Capital Fund IX, L.P.	—	Financial assets at fair value through profit or loss - non-current	—	846,164	1.75%	864,164
Center Laboratories, Inc.	GL China Opportunities Fund III L.P.	—	Financial assets at fair value through profit or loss - non-current	—	721,628	4.17%	721,628
Center Laboratories, Inc.	Vivo Innovation Fund II, L.P.	—	Financial assets at fair value through profit or loss - non-current	—	308,594	5.06%	308,594
Center Laboratories, Inc.	Chengwei GP Participation Fund, L.P.	—	Financial assets at fair value through profit or loss - non-current	—	549,933	20.60%	549,933
Center Laboratories, Inc.	Vaxon Investment Inc.	—	Financial assets at fair value through profit or loss - non-current	1,500	54,416	15.00%	54,416
Center Laboratories, Inc.	Helicase Venture Fund I, L.P.	—	Financial assets at fair value through profit or loss - non-current	—	62,066	30.00%	62,066
Center Laboratories, Inc.	Fangyuan PCJ Fund II L.P.	—	Financial assets at fair value through profit or loss - non-current	—	172,873	19.80%	172,873
Center Laboratories, Inc.	GL China Opportunities Fund IV L.P.	—	Financial assets at fair value through profit or loss - non-current	—	1,084,320	16.39%	1,084,320
Center Laboratories, Inc.	Efficient Biomedical Corp.	—	Financial assets at fair value through profit or loss - non-current	160,000	14,530	16.00%	14,530
Center Laboratories, Inc.	T-E Pharma Holding(Cayman) Preferred stock	—	Financial assets at fair value through profit or loss - non-current	18,750,000	86,911	6.37%	86,911
Center Laboratories, Inc.	Onward Therapeutics SA Preferred stock	—	Financial assets at fair value through profit or loss - non-current	11,316,700	350,273	17.75%	350,273
Center Laboratories, Inc.	TransPacific Medtech Co., Ltd.	—	Financial assets at fair value through profit or loss - non-current	3,129	29,409	31.29%	29,409
Center Laboratories, Inc.	T-E Meds Holding(Cayman)	—	Financial assets at fair value through profit or loss - non-current	2,500,000	28,027	1.17%	28,027
Center Laboratories, Inc.	AmMax,BIO, INC.	—	Financial assets at fair value through profit or loss - non-current	602,200	8,615	1.59%	8,615

Name of Company Held	Type and Name of Securities	Relationship with Securities Issuer	Financial Statement Account	Ending Balance			
				Shares	Carrying Amount	Shareholding percentage	Fair Value
Center Laboratories, Inc.	AiViva_Series A Preferred Share	—	Financial assets at fair value through profit or loss - non-current	4,031,052	16,789	16.54%	16,789
Center Laboratories, Inc.	Shine-On BioMedical Co., Ltd.	—	Financial assets at fair value through profit or loss - non-current	2,827,813	179,504	5.68%	179,504
Center Laboratories, Inc.	iXensor Co., Ltd.	—	Financial assets at fair value through profit or loss - non-current	1,864,066	12,010	4.59%	12,010
Center Laboratories, Inc.	Taiwan Depository & Clearing Corporation	—	Financial assets at fair value through profit or loss - non-current	12,500	2,013	—	2,013
Center Laboratories, Inc.	Ausnutria Dairy Corporation Ltd.	—	Financial assets at fair value through profit or loss - non-current	117,635,644	1,219,817	6.61%	1,219,817
Center Laboratories, Inc.	Ever Supreme Bio Technology Co., Ltd.	—	Financial assets at fair value through profit or loss - non-current	10,316,880	1,913,781	11.78%	1,913,781
Center Laboratories, Inc.	Ever Fortune. AI Co., Ltd.	—	Financial assets at fair value through profit or loss - non-current	3,697,000	266,923	3.88%	266,923
Center Laboratories, Inc.	Adimmune Corporation	—	Financial assets at fair value through profit or loss - non-current	3,281,000	62,175	0.76%	62,175
Centerlab Investment Holding Limited	Shuimu Development Limited	—	Financial assets at fair value through profit or loss - non-current	—	16,742	33.00%	16,742
Centerlab Investment Holding Limited	HebeCell Holding Limited - Preferred stock	—	Financial assets at fair value through profit or loss - non-current	31,710	—	1.14%	—
Centerlab Investment Holding Limited	GL JKP Holding L.P.	—	Financial assets at fair value through profit or loss - non-current	—	365,718	8.00%	365,718
Centerlab Investment Holding Limited	Nanjing Chengwei Shiji Equity Investment Partnership (Limited Partnership)	—	Financial assets at fair value through profit or loss - non-current	—	520,467	10.00%	520,467
Centerlab Investment Holding Limited	UAC Technology (Jiaxing) Co., Ltd.	—	Financial assets at fair value through profit or loss - non-current	—	174,324	16.20%	174,324
Centerlab Investment Holding Limited	Bioflag Nutrition Corporation(KY)	—	Financial assets at fair value through profit or loss - non-current	5,038,672	172,656	10.26%	172,656
Center Laboratories Limited(HK)	Shanghai Bao Pharmaceutical Co., Ltd.	—	Financial assets at fair value through profit or loss - non-current	7,981,066	2,305,381	13.85%	2,305,381
Center Biotherapeutics, Inc.	Scindy Pharmaceutical (Suzhou)	—	Financial assets at fair value through profit or loss - non-current	—	12,857	15.79%	12,857
Center Biotherapeutics, Inc.	GenEditBio Limited(Cayman)	—	Financial assets at fair value through profit or loss - non-current	4,322,881	61,545	2.86%	61,545
Center Venture Holding I Limited	Jacobio(CAY)Pharmaceuticals Co., Ltd.	—	Financial assets at fair value through profit or loss - current	635,300	24,611	0.08%	24,611
Center Venture Holding I Limited (HK)	Jacobio(CAY)Pharmaceuticals Co., Ltd.	—	Financial assets at fair value through profit or loss - non-current	78,801,300	3,052,660	9.95%	3,052,660
Center Venture Holding II Limited (HK)	Guangzhou Hybot Technology Co., Ltd.	—	Financial assets at fair value through profit or loss - non-current	—	452,420	8.33%	452,420

Name of Company Held	Type and Name of Securities	Relationship with Securities Issuer	Financial Statement Account	Ending Balance			
				Shares	Carrying Amount	Shareholding percentage	Fair Value
BioEngine Technology Development Inc.	Jacobio(CAY)Pharmaceuticals Co., Ltd.	—	Financial assets at fair value through profit or loss - current	4,361,400	168,955	0.55%	168,955
BioEngine Technology Development Inc.	Adimmune Corporation	—	Financial assets at fair value through profit or loss - non-current	11,415,000	216,314	2.66%	216,314

Table 2

Information on investees:(excluding information on investments in mainland china)

In Thousands of New Taiwan Dollars, Except for Shares

Investor Company	Investee Company	Address	Main Businesses	Original Investment Amount		Balance as of September 30, 2025			Net Income (Loss) of the Investee	Share of Profit (Loss) Investee	Note
				September 30, 2025	December 31, 2024	Shares	Percentage	Carrying Amount			
Center Laboratories, Inc.	Fangyuan Growth SPC PCJ Healthcare Fund SP	Sertus Chambers, Governors Square, Suite # 5-204, 23 Lime Tree Bay Avenue, P.O. Box 2547, Grand Cayman, KY1-1104, Cayman Islands	Investment	211,653	280,021	—	33.33%	330,172	188,296	62,759	—
Center Laboratories, Inc.	PCJ Capital Management Limited	Sertus Chambers, Governors Square, Suite # 5-204, 23 Lime Tree Bay Avenue, P.O. Box 2547, Grand Cayman, KY1-1104, Cayman Islands	Management consultant	—	—	—	25%	—	—	—	—
Center Laboratories, Inc.	Center Biotherapeutics Inc.	Sea Meadow House, Blackburne Highway, PO Box 116, Road Town, Tortola, British Virgin Islands	Investment	66,152	66,152	2,228,283	100.00%	87,652	(32,211)	(32,211)	Subsidiary
Center Laboratories, Inc.	BioEngine Technology Development Inc.	7F., No. 3-2, Park St., Nangang Dist., Taipei City, Taiwan (R.O.C.)	Investment management consultant	428,777	428,777	98,437,500	100.00%	721,681	77,522	100,285	Subsidiary
Center Laboratories, Inc.	Mycenax Biotech Inc.	7F., No. 66, Shengyi 2nd Rd., Zhubei City, Hsinchu County, Taiwan (R.O.C.), Hsinchu Science Park	Manufacturing and sales of biopharmaceuticals	1,003,282	1,003,282	41,974,314	20.26%	340,994	(396,178)	(80,304)	The Company's legal representative is the Chairman of this Company
Center Laboratories, Inc.	TOT BIOPHARM International Company Limited	15/F MAY MAY BUILDING, 683-685 NATHAN ROAD KOWLOON, HONG KONG	Investment	2,433,620	2,433,620	213,311,700	27.60%	2,813,204	(14,629)	(15,515)	—
Center Laboratories, Inc.	Centerlab Investment Holding Limited(HK)	FLAT/RM 1204, Yu Sung Boon Bldg., 107-111 Des Voeux Road, Central, Hong Kong	Investment	531,114	1,194,127	17,277,934	100.00%	1,269,933	11,721	11,721	Subsidiary
Center Laboratories, Inc.	Center Laboratories Limited(HK)	FLAT/RM 1204, Yu Sung Boon Bldg., 107-111 Des Voeux Road, Central, Hong Kong	Investment	1,188,313	1,188,313	39,871,908	100.00%	2,305,366	(140,325)	(140,325)	Subsidiary
Center Laboratories, Inc.	Lumosa Therapeutics Co., Ltd.	4F-1, No. 3-2, Park St., Nangang Dist., Taipei City, Taiwan (R.O.C.)	Drug development	1,856,191	1,841,579	57,863,874	34.35%	548,064	(284,910)	(97,607)	—
Center Laboratories, Inc.	Medeon Biodesign, Inc.	5F., No. 116, Hougang St., Shilin Dist., Taipei City, Taiwan (R.O.C.)	Medical device development	683,835	770,495	24,328,028	26.37%	309,405	(530,947)	(153,836)	—
Center Laboratories, Inc.	BioGend Therapeutics Co., Ltd.	4F, No. 3-2, Park St., Nangang Dist., Taipei City, Taiwan (R.O.C.)	Development of orthopedic medical devices	512,676	512,676	37,580,008	30.22%	263,000	(63,349)	(20,566)	—

Investor Company	Investee Company	Address	Main Businesses	Original Investment Amount		Balance as of September 30, 2025			Net Income (Loss) of the Investee	Share of Profit (Loss) Investee	Note
				September 30, 2025	December 31, 2024	Shares	Percentage	Carrying Amount			
Center Laboratories, Inc.	A2 + Healthcare Venture Fund L.P.	6F., No. 135, Section 3, Minsheng East Road, Songshan District, Taipei City, Taiwan (R.O.C.)	Venture capital	250,000	250,000	—	49.50%	310,822	86,469	42,806	—
Center Laboratories, Inc.	Anya Biopharm Inc.	6F., No. 378, Changchun Rd., Zhongshan Dist., Taipei City, Taiwan (R.O.C.)	Drug development	16,265	16,277	8,270,369	16.84%	78,380	(63,393)	(14,680)	—
Center Laboratories, Inc.	Center Venture Holding I Limited	FLAT/RM 1204, Yu Sung Boon Bldg., 107-111 Des Voeux Road, Central, Hong Kong	Investment	1,913,443	1,913,443	1	100%	3,077,295	2,651,335	2,651,335	Subsidiary
Center Laboratories, Inc.	Center Venture Holding II Limited	FLAT/RM 1204, Yu Sung Boon Bldg., 107-111 Des Voeux Road, Central, Hong Kong	Investment	451,032	451,032	13,929,351	100%	452,449	(33,209)	(33,209)	Subsidiary
Center Laboratories, Inc.	Center Venture Holding III Limited	Level 2, Lotemau Centre Building, Vaea Street, Apia, Samoa	Investment	—	—	1	100%	—	—	—	Subsidiary
Center Laboratories, Inc.	Cytoengine Co., Ltd.	4F., No. 3-2, Park St., Nangang Dist., Taipei City, Taiwan (R.O.C.)	Drug development	50,000	50,000	5,000,000	40%	11,131	(11,761)	(4,705)	—
Center Laboratories, Inc.	KriSan Biotech Co., Ltd.	5th Floor, No. 28, Lane 31, Section 1, Huan Dong Road, Xinxiqu, Tainan City, Taiwan (R.O.C.)	Western pharmaceutical manufacturing industry	201,500	201,500	10,075,000	17.53%	158,387	(69,424)	(15,568)	—
Center Laboratories, Inc.	Bioflag International Corporation	4th Floor, Harbour Place, 103 South church Street, P.O.Box 10240, Grand Cayman KY1-1002, Cayman Islands	Investment	2,210,039	1,388,476	66,654,539	100%	1,409,248	(13,278)	(48,907)	Subsidiary
Centerlab Investment Holding Limited(HK)	ASEAN Bio & Medical Platform Investment L.P.	25F, City Air Tower, 159-9, Samsung-dong, Gangnam-gu, Seoul, Korea	Investment	53,945	53,945	—	30.00%	14,515	—	—	—
Bioflag International Corporation	Bioflag Co., Ltd.	Sea Meadow House, Blackburne Highway, Road Town, British Virgin Islands	Investment	—	1,836,445	—	—	—	4,509	4,509	Sub-subsidiary
Bioflag International Corporation	Glac Biotech Co., Ltd.	4F-2, No. 17, Guoji Rd., Xinshi Dist., Tainan City, Taiwan (R.O.C.)	Manufacturing and sales of functional probiotics	1,092,386	—	72,171,000	100.00%	1,674,510	(11,065)	(15,579)	Sub-subsidiary
Bioflag Co., Ltd.	Glac Biotech Co., Ltd.	4F-2, No. 17, Guoji Rd., Xinshi Dist., Tainan City, Taiwan (R.O.C.)	Manufacturing and sales of functional probiotics	—	1,704,696	—	100.00%	—	(11,065)	4,514	Sub-subsidiary
Glac Biotech Co., Ltd.	OmniPro Biotech Co., Ltd.	No. 10, Xinsheng St., Minxiong Township, Chiayi County, Taiwan (R.O.C)	General food manufacturing	15,000	15,000	1,500,000	100.00%	2,136	(79)	(79)	Sub-subsidiary
Glac Biotech Co., Ltd.	Ezadd Co., Ltd.	7F., No. 3-2, Park St., Nangang Dist., Taipei City, Taiwan (R.O.C.)	Functional probiotics sales	1,990	1,990	199,000	99.50%	1,235	1	1	Sub-subsidiary

Investor Company	Investee Company	Address	Main Businesses	Original Investment Amount		Balance as of September 30, 2025			Net Income (Loss) of the Investee	Share of Profit (Loss) Investee	Note
				September 30, 2025	December 31, 2024	Shares	Percentage	Carrying Amount			
BioEngine Technology Development Inc.	Lumosa Therapeutics Co., Ltd.	4F-1, No. 3-2, Park St., Nangang Dist., Taipei City, Taiwan (R.O.C.)	Drug development	31,683	31,683	1,053,218	0.62%	19,391	(284,910)	(1,778)	—
BioEngine Technology Development Inc.	TOT BIOPHARM International Company Limited	15/F MAY MAY BUILDING, 683-685 NATHAN ROAD KOWLOON, HONG KONG	Investment	84,468	84,468	7,646,300	0.99%	103,080	(14,629)	(556)	—
BioEngine Technology Development Inc.	BioEngine Development I Limited	FLAT/RM 1204, YU SUNG BOON BLDG., 107-111 DES VOEUX ROAD, CENTRAL, HONG KONG	Investment	22,890	22,890	1,000,000	100.00%	19,173	(513)	(513)	Sub-subsidiary
BioEngine Technology Development Inc.	A2+ Biotech Consulting Co., Ltd.	6F., No. 135, Section 3, Minsheng East Road, Songshan District, Taipei City, Taiwan (R.O.C.)	Management consultant	4,000	4,000	400,000	33.33%	4,922	1,915	638	—
BioEngine Technology Development Inc.	Anya Biopharm Inc.	6F., No. 378, Changchun Rd., Zhongshan Dist., Taipei City, Taiwan (R.O.C.)	Drug development	66,091	68,400	2,261,000	4.60%	21,366	(63,393)	(4,151)	—
BioEngine Technology Development Inc.	Mycenax Biotech Inc.	7F., No. 66, Shengyi 2nd Rd., Biomedical 2nd Road, 7th Floor, Zhubei City, Hsinchu County, Taiwan (R.O.C.), Hsinchu Science Park	Manufacturing and sales of biopharmaceuticals	32,370	32,370	780,000	0.38%	6,182	(396,178)	(1,492)	—

Table 3

Information on Investment in Mainland China:

Investee Company	Main Businesses	Paid-in Capital	Method of Investment (Note 1)	Accumulated Outflow of Investment from Taiwan as of January 1, 2025	Investment Flows		Accumulated Outflow of Investment from Taiwan as of September 30, 2025	Net Income (Loss) of the Investee Company	Percentage of Ownership	Share of Profits (Losses) (Note 2)	Carrying Amount as of September 30, 2025	Accumulated Inward Remittance of Earnings as of September 30, 2025
					Outflow	Inflow						
TOT BIOPHARM Co., Ltd.	Production, research and development of anti-cancer capsules and liposome injection	USD NT\$222,450 thousand	(2) TOT BIOPHARM International Company Limited (Hong Kong)	698,807	—	—	698,807	24,566	27.60%	6,780	818,944	—
Jiang Su Tung Yang Biopharm Tech Co., Ltd.	Sales, research and development of western medicine	USD NT\$2,000 thousand	(2) TOT BIOPHARM International Company Limited (Hong Kong)	13,684	—	—	13,684	(204)	27.60%	(56)	7,413	—
Dongyuan Biotech (Shanghai) Co., Ltd.	Pharmaceutical research and development	USD NT\$3,730 thousand	(2) TOT BIOPHARM International Company Limited (Hong Kong)	24,956	—	—	24,956	(359)	27.60%	(99)	3,855	—
Shanghai Bao Pharmaceutical Co., Ltd.	Company specializing in the development of recombinant proteins and antibody drugs	RMB NT\$46,860 thousand	(2) Center Laboratories Limited(HK)	1,188,191	—	—	1,188,191	—	13.85%	—	2,305,381	—
Beijing Jinkangpu Food Science & Technology Co., Ltd.	Sub-packaging and production of food additives and compound food additives	RMB NT\$10,000 thousand	(2) Centerlab Investment Holding Limited	198,471	—	—	198,471	—	5.00%	—	329,146	—
Beijing Kangpuni Detection Technology Co., Ltd.	Technology of Detection	RMB NT\$1,000 thousand	(2) Centerlab Investment Holding Limited	22,053	—	—	22,053	—	5.00%	—	36,572	—

Investee Company	Main Businesses	Paid-in Capital	Method of Investment (Note 1)	Accumulated Outflow of Investment from Taiwan as of January 1, 2025	Investment Flows		Accumulated Outflow of Investment from Taiwan as of September 30, 2025	Net Income (Loss) of the Investee Company	Percentage of Ownership	Share of Profits (Losses) (Note 2)	Carrying Amount as of September 30, 2025	Accumulated Inward Remittance of Earnings as of September 30, 2025
					Outflow	Inflow						
Scindy Pharmaceutical (Suzhou)	Medical Research and Experimental Development	RMB NT\$15,833 thousand	(2) Center Biotherapeutics Inc.	66,120	—	—	66,120	—	15.79%	—	12,857	—
Nanjing Chengwei Shiji Equity Investment Partnership (Limited Partnership)	Venture capital	RMB NT\$660,000 thousand	(2) Centerlab Investment Holding Limited	391,214	98,538	—	489,752	—	10.00%	—	520,467	—
UAC Technology (Jiaxing) Co., Ltd.	Manufacture and Design of Specialized Equipment	EUR NT\$23,045 thousand	(2) Centerlab Investment Holding Limited	174,143	—	—	174,143	—	16.20%	—	174,324	—
Bioflag (Huai'an) Co., Ltd.	Biological health product research and development and related technical consultation	RMB NT\$109,218 thousand	(2) Centerlab Investment Holding Limited Transfer of Investment to Bioflag	—	—	—	—	—	10.26%	—	172,656	—
Bioflag (Anhui) Co., Ltd.	Research and development, production, and sales of probiotics and other microorganisms and related products	RMB NT\$36,242 thousand	(2) Centerlab Investment Holding Limited Transfer of Investment to Bioflag	—	—	—	—	—	10.26%	—		—
Beijing Shundu Pharmaceutical Research Institute Co., Ltd.	Pharmaceutical technology development and consulting	RMB NT\$6,123 thousand	(2) BioEngine Development I Limited	—	—	—	—	(511)	100%	(511)	10,585	—
Guangzhou Hybot Technology Co., Ltd.	Sales of new energy vehicles	RMB NT\$300,000 thousand	(2) Center Venture Holding II Limited	451,000	—	—	451,000	—	8.33%	—	452,420	—

Company name	Accumulated Investment in Mainland China as of September 30, 2025	Investment Amounts Authorized by Investment Commission, MOEA	Upper Limit on the Company's Investments in Mainland China
			Net worth * 60%
Center Laboratories, Inc.	NT\$2,907,273 thousand	USD 80,373 thousand RMB 664,475 thousand EUR 5,500 thousand	11,782,451

Note1: Method of investment can be divided into three types as follows:

- (1) Direct investment in Mainland China.
- (2) Investment in Mainland China through a company in a third area (Please indicate the invested company in a third area).
- (3) Other methods.

Note2: The recognition of investment gains and losses for the current period is based on unaudited financial statements.

Table 4 Parent-Subsidiary Company Business Relation and Important Transactions - For the nine months ended September 30, 2025

In Thousands of New Taiwan Dollars

No. (Note 1)	Name of Company	Name of Counterparty	Nature of Relationship (Note 2)	Intercompany Transactions			
				Financial Statement Account	Amount	Transaction Terms	Percentage of Consolidated Net Revenue or Total Assets (Note 3)
0	Center Laboratories, Inc.	Glac Biotech Co., Ltd.	1	Other receivables	Other payables	922	Based on contracts signed between both parties
		Glac Biotech Co., Ltd.	1	Guarantee deposits	Refundable deposits	1,834	Based on contracts signed between both parties
		Glac Biotech Co., Ltd.	1	Lease income/Investment loss	Depreciation/Interest expenses	8,920	Based on contracts signed between both parties
		Glac Biotech Co., Ltd.	1	Other receivables/Long-term investment	Lease liabilities	4,709	Based on contracts signed between both parties
					Right-of-use assets/Lease liabilities	77,937	Based on contracts signed between both parties
		Glac Biotech Co., Ltd.	1	Lease income	Rental expenses	704	Based on contracts signed between both parties
		Glac Biotech Co., Ltd.	1	Other income	Other expenses	4,900	Based on contracts signed between both parties
		BioEngine Technology Development Inc.	1	Other income	Entrusted management fee	654	Based on contracts signed between both parties
	Glac Biotech Co., Ltd.	OmniPro Biotech Co., Ltd.	1	Accounts receivable	Accounts payable	1,291	Based on contracts signed between both parties
		OmniPro Biotech Co., Ltd.	1	Sales revenue	Purchases	965	Based on contracts signed between both parties
							0.09%

Note1: The business transaction information between the parent company and its subsidiaries should be indicated in the serial number column, respectively. The method of filling in the serial number is as follows:

- (1) For the parent, please indicate "0" in the code column.
- (2) For investees, please indicate "1" in the code column and arrange the investees by company type.

Note2: There are five types of relationship with the trader. Just indicate the type:

- (1) The parent to the subsidiary.
- (2) Subsidiary to the parent.
- (3) Between subsidiaries.

Note3: The calculation of the ratio of the transaction amount to the consolidated total revenue or total assets. If it is an asset-liability account, it is calculated as the ending balance of the consolidated total assets; if it is a profit and loss account, the cumulative amount in the period accounts for the total consolidated total. It is calculated by the method of receipt.

Table 4 Parent-Subsidiary Company Business Relation and Important Transactions - For the nine months ended September 30, 2024

In Thousands of New Taiwan Dollars

No. (Note 1)	Name of Company	Name of Counterparty	Nature of Relationship (Note 2)	Intercompany Transactions			
				Financial Statement Account	Amount	Transaction Terms	Percentage of Consolidated Net Revenue or Total Assets (Note 3)
0	Center Laboratories, Inc.	Glac Biotech Co., Ltd.	1	Other receivables	Other payables	1,339	Based on contracts signed between both parties
		Glac Biotech Co., Ltd.	1	Advance receipts	Prepaid expenses	628	Based on contracts signed between both parties
		Glac Biotech Co., Ltd.	1	Guarantee deposits	Refundable deposits	1,105	Based on contracts signed between both parties
		Glac Biotech Co., Ltd.	1	Lease income/Investment loss	Depreciation/Interest expenses	5,428	Based on contracts signed between both parties
		Glac Biotech Co., Ltd.	1	Lease Income	Rental expenses	712	Based on contracts signed between both parties
		Glac Biotech Co., Ltd.	1	Other income	Other expenses	3,705	Based on contracts signed between both parties
		Glac Biotech Co., Ltd.	1	Other receivables/Long-term investment	Lease liabilities/Right-of-use assets	2,905	Based on contracts signed between both parties
		BioEngine Technology Development Inc.	1	Other income	Entrusted management fee	312	Based on contracts signed between both parties
		Bioflag International Corporation	1	Financial assets at amortized cost - non-current	Bonds payable	200,000	Based on contracts signed between both parties
		Bioflag International Corporation	1	Other receivables	Other payables	15,775	Based on contracts signed between both parties
		Bioflag International Corporation	1	Interest income	Interest expenses	6,136	Based on contracts signed between both parties
		Center Biotherapeutics Inc.	1	Interest expenses	Interest income	59	Based on contracts signed between both parties
	Bioflag International Corporation	Bioflag Co., Ltd.	1	Other receivables	Other payables	263,836	Based on contracts signed between both parties
	Genlac Biotech Inc.	Bioflag Co., Ltd.	1	Interest income	Interest expenses	529	Based on contracts signed between both parties
		Bioflag Co., Ltd.	2	Other receivables	Other payables	158,250	Based on contracts signed between both parties
	Glac Biotech Co., Ltd.	OmniPro Biotech Co., Ltd.	1	Accounts receivable	Accounts payable	1,050	Based on contracts signed between both parties

No. (Note 1)	Name of Company	Name of Counterparty	Nature of Relationship (Note 2)	Intercompany Transactions			
				Financial Statement Account	Amount	Transaction Terms	Percentage of Consolidated Net Revenue or Total Assets (Note 3)
		OmniPro Biotech Co., Ltd.	1	Sales revenue	Cost of goods sold	597	Based on contracts signed between both parties 0.05%
		OmniPro Biotech Co., Ltd.	1	Commission expenses	Other income	38	Based on contracts signed between both parties —

Note1: The business transaction information between the parent company and its subsidiaries should be indicated in the serial number column, respectively. The method of filling in the serial number is as follows:

- (1) For the parent, please indicate “0” in the code column.
- (2) For investees, please indicate “1” in the code column and arrange the investees by company type.

Note2: There are five types of relationship with the trader. Just indicate the type:

- (1) The parent to the subsidiary.
- (2) Subsidiary to the parent.
- (3) Between subsidiaries.

Note3: The calculation of the ratio of the transaction amount to the consolidated total revenue or total assets. If it is an asset-liability account, it is calculated as the ending balance of the consolidated total assets; if it is a profit and loss account, the cumulative amount in the period accounts for the total consolidated total. It is calculated by the method of receipt.